var title_f33_48_34560="Oral ulcer Behcets PI";
var content_f33_48_34560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral ulcer Behcet's",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34560=[""].join("\n");
var outline_f33_48_34560=null;
var title_f33_48_34561="Treatment protocols for hepatobiliary cancer";
var content_f33_48_34561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for hepatobiliary cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34561/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/48/34561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1090276\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with biliary and hepatocellular cancer.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with hepatobiliary cancer. Additional regimens may be added over time, particularly as treatment for hepatobiliary cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with hepatobiliary cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"       \"Systemic therapy for advanced cholangiocarcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=see_link\">",
"       \"Treatment of advanced, unresectable gallbladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3674?source=see_link\">",
"       \"Ampullary carcinoma: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link\">",
"       \"Systemic treatment for advanced hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1090199\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934552054\">",
"    <span class=\"h2\">",
"     Short-term infusional fluorouracil plus leucovorin for advanced gastrointestinal cancer (modified de Gramont schedule)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H934552083\">",
"    <span class=\"h2\">",
"     Single agent gemcitabine for adjuvant treatment of biliary tract cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81436 \" href=\"mobipreview.htm?26/2/26669\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1090566\">",
"    <span class=\"h2\">",
"     Single agent gemcitabine for metastatic biliary tract cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60330 \" href=\"mobipreview.htm?35/56/36749\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10666543\">",
"    <span class=\"h2\">",
"     Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85683 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34561=[""].join("\n");
var outline_f33_48_34561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1090276\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1090199\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H934552054\">",
"      Short-term infusional fluorouracil plus leucovorin for advanced gastrointestinal cancer (modified de Gramont schedule)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H934552083\">",
"      Single agent gemcitabine for adjuvant treatment of biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1090566\">",
"      Single agent gemcitabine for metastatic biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10666543\">",
"      Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 1\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/2/26669\" title=\"table 2\">",
"      Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/56/36749\" title=\"table 3\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 4\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3674?source=related_link\">",
"      Ampullary carcinoma: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33977?source=related_link\">",
"      Treatment of advanced, unresectable gallbladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34562="Algorithm for chronic weight loss in children and adolescents";
var content_f33_48_34562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 644px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for chronic weight loss in children and adolescents*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 624px; height: 809px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Chronic weight loss refers to decreased body weight over more than one to two weeks.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Fever may",
"      <strong>",
"       not",
"      </strong>",
"      always be present in patients with weight loss caused by malignancy.",
"      <br>",
"       &Delta; Several chronic infections may cause weight loss in association with prolonged fever and nonspecific and variable clinical findings such as lymphadenopathy, hepatitis, and myalgias including brucellosis, leptospirosis, tularemia, and Epstein-Barr virus. For more information&nbsp;refer to UpToDate topics on fever of unknown origin.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34562=[""].join("\n");
var outline_f33_48_34562=null;
var title_f33_48_34563="EtCO2 wave interpretation a";
var content_f33_48_34563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Capnographic airway assessment for procedural sedation and analgesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 654px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Krauss, B, Hess, DR. Capnography for Procedural Sedation and Analgesia in the Emergency Department. Annals of Emergency Medicine 2007; 50:172. Copyright &copy; 2007 The American College of Emergency Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34563=[""].join("\n");
var outline_f33_48_34563=null;
var title_f33_48_34564="Vaginal hysterectomy";
var content_f33_48_34564=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaginal hysterectomy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/48/34564/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34564/contributors\" id=\"au5417\">",
"       Thomas G Stovall, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34564/contributors\" id=\"au5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/48/34564/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34564/contributors\" id=\"se2521\">",
"       Howard T Sharp, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/48/34564/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34564/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/48/34564?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal hysterectomy is a procedure in which the uterus is surgically removed through the vagina. One or both ovaries and fallopian tubes may be removed during the procedure as well; removal of both ovaries and fallopian tubes is called bilateral salpingo-oophorectomy (BSO) (",
"     <a class=\"graphic graphic_figure graphicRef71521 \" href=\"mobipreview.htm?19/49/20243\">",
"      figure 1",
"     </a>",
"     ). A vaginal approach may be used if the uterus is not greatly enlarged, and if the reason for the surgery is not related to cancer.",
"    </p>",
"    <p>",
"     Studies have shown that vaginal hysterectomy has fewer complications, requires a shorter hospital stay, and allows a faster recovery compared to removal of the uterus through an abdominal incision (abdominal hysterectomy). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=see_link\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FEMALE ANATOMY",
"     </span>",
"    </p>",
"    <p>",
"     A brief review of female reproductive anatomy may be of help in understanding hysterectomy (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The uterus is a hollow, pear-shaped muscular organ located in the lower abdomen or pelvis. One end of each fallopian tube opens into the side of the uterus, at the upper end, and the other end of the fallopian tube lies next to an ovary. At its lower end, the uterus narrows and opens into the vagina. The lower end of the uterus is called the cervix. The ovaries lie next to and slightly behind the uterus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      REASONS FOR VAGINAL HYSTERECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     A hysterectomy may be advised for a number of conditions. For some of these conditions, there may be alternatives to hysterectomy, which are described below. (See",
"     <a class=\"local\" href=\"#H27\">",
"      'Alternatives to hysterectomy'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Abnormal uterine bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excessive uterine bleeding, called menorrhagia, can lead to anemia (low blood iron count), fatigue, and contribute to missed days at work or school. Menorrhagia is generally defined as bleeding that lasts longer than seven days or saturates more than one pad per hour for several hours. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30484?source=see_link\">",
"      \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Irregular uterine bleeding, called metrorrhagia, can also occur in women with menorrhagia. Metrorrhagia is defined as bleeding or spotting that occurs at times other than during the expected menstrual period.",
"    </p>",
"    <p>",
"     Menorrhagia and metrorrhagia are generally treated first with medication or other surgical alternatives to hysterectomy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .) However, abnormal uterine bleeding that does not improve with conservative treatments may require hysterectomy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Fibroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fibroids (also known as leiomyoma) are noncancerous growths of uterine muscle. Fibroids may become larger during pregnancy, and typically shrink after menopause. They may cause excessive and irregular uterine bleeding. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"      \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Pelvic organ prolapse",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic organ prolapse occurs due to stretching and weakening of the pelvic muscles and ligaments. This allows the uterus to fall (or prolapse) into the vagina. It is usually related to pregnancy, vaginal childbirth, genetic factors, chronic constipation, or lifestyle factors (repeated heavy lifting over the lifetime).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Cervical abnormalities",
"     </span>",
"     &nbsp;&mdash;&nbsp;Precancer or carcinoma in situ (CIN 3) of the cervix that does not resolve after other procedures (such as cone biopsy, laser or cryosurgery) may require hysterectomy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=see_link\">",
"      \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=see_link\">",
"      \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Endometrial hyperplasia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endometrial hyperplasia is the term used to describe excessive growth of the endometrium (the tissue that lines the uterus). It can sometimes lead to endometrial cancer. Although endometrial hyperplasia can often be treated with medication, a hysterectomy is sometimes needed or preferred to medical therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Chronic pelvic pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic pelvic pain can be due to the effects of endometriosis or scarring (adhesions) in the pelvis and between pelvic organs. However, pelvic pain can also be caused by other sources, including the gastrointestinal and urinary systems. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/55/32627?source=see_link\">",
"      \"Patient information: Chronic pelvic pain in women (Beyond the Basics)\"",
"     </a>",
"     .) It is important for a woman with pelvic pain to ask about the probability that her pain will improve after hysterectomy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PRE-OPERATIVE PLANNING AND EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     Before surgery, there are two main decisions that need to be made: whether the ovaries should be removed, and whether estrogen replacement therapy is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Removal of ovaries",
"     </span>",
"     &nbsp;&mdash;&nbsp;A hysterectomy does not involve removing the ovaries, but they may be removed at the same time as hysterectomy; this procedure is known as oophorectomy. The decision to remove the ovaries depends upon several considerations. Occasionally, it may not be possible to remove the ovaries due to scar tissue or other factors that increase the risk of removal.",
"    </p>",
"    <p>",
"     Premenopausal women may decide to keep the ovaries to provide a continued, natural source of hormones, including estrogen, progesterone, and testosterone. These hormones are important in maintaining sexual interest and preventing hot flashes and loss of bone density loss. On the other hand, women who have menstrual cycle-related migraines, epilepsy, or severe premenstrual syndrome may have an improvement in symptoms when hormone levels are reduced by removal of the ovaries. Individuals should discuss the risks and preferences with a doctor before surgery.",
"    </p>",
"    <p>",
"     Postmenopausal women are usually advised to have their ovaries removed because of a small risk of developing ovarian cancer at some point during their lifetime. This benefit of removing the ovaries appears to outweigh the benefit of continued hormone production, as described above.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Estrogen therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Estrogen therapy (ET) may be recommended after surgery for women who had their ovaries removed. Women who have not reached menopause may use ET to avoid hot flashes, night sweats, and loss of bone density, which may occur when the ovaries are surgically removed. Women who plan to use ET should talk with their clinician about the risks and benefits, and about how long to use this treatment.",
"    </p>",
"    <p>",
"     In younger women who retain their ovaries, ET may be needed at a later date if the ovaries stop functioning earlier than expected.",
"    </p>",
"    <p>",
"     Women who have completed menopause generally do not require ET after hysterectomy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=see_link\">",
"      \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pre-operative testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Standard pre-operative testing may include a physical examination, EKG, chest x-ray, and blood testing, depending upon age and other medical conditions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      VAGINAL HYSTERECTOMY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal hysterectomy is performed in a hospital setting, and generally requires one to two hours in the operating room. Patients are given general or spinal anesthesia plus sedation so that they feel no pain. Heart rate, blood pressure, blood loss, and respiration are closely observed throughout the procedure. After surgery, patients are transferred to the recovery room (also known as the post-anesthesia care unit) so that they can be monitored while waking up. &nbsp;Most patients will then be transferred to a hospital room and will stay one to two days.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      LAPAROSCOPICALLY ASSISTED VAGINAL HYSTERECTOMY (LAVH)",
"     </span>",
"    </p>",
"    <p>",
"     Laparoscopically assisted vaginal hysterectomy (LAVH) is done by some surgeons to assist with the vaginal hysterectomy procedure. A laparoscope is a surgical instrument inserted through a small incision in the abdomen and pelvis. Using the scope, the surgeon can more easily see the uterus, ovaries, and the tissues that surround these organs within the pelvis (",
"     <a class=\"graphic graphic_figure graphicRef60328 \" href=\"mobipreview.htm?35/63/36851\">",
"      figure 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In addition, instruments may be used, along with the laparoscope, to facilitate the removal of the uterus through the vagina. LAVH might be recommended for a woman with an enlarged uterus, history of prior pelvic surgery, endometriosis, or other factors that could complicate a traditional vaginal hysterectomy. Women generally recover faster after a vaginal hysterectomy or LAVH, as compared to women who have abdominal hysterectomy.",
"    </p>",
"    <p>",
"     However, not all surgeons use laparoscopy since additional training, experience, and equipment is necessary. Patients should talk to their surgeon regarding the best procedure for their individual situation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      NEED FOR ABDOMINAL HYSTERECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     After surgery has begun, the surgeon may find conditions, such as extensive scar tissue, that require him or her to make an abdominal incision to remove the uterus. Sometimes these conditions are not apparent before surgery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      VAGINAL HYSTERECTOMY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     A number of complications can occur as a result of hysterectomy. Fortunately, most can be easily managed and do not cause long-term problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Hemorrhage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excessive bleeding (hemorrhage) occurs in a small number of cases. Excessive bleeding may require a blood transfusion",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a return to the operating room to find and stop it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low-grade fever is common after hysterectomy, is not always caused by infection, and usually resolves without treatment. However, a high or persistent fever may signal an infection. Serious infection occurs in less than five percent of women, and can usually be treated with intravenous antibiotics. Much less commonly, patients require another surgical procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Constipation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Constipation occurs in most women following hysterectomy, and can usually be controlled with a regimen of stool softeners, dietary fiber, and laxatives.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Urinary retention",
"     </span>",
"     &nbsp;&mdash;&nbsp;Urinary retention, or the inability to pass urine, can occur after vaginal hysterectomy. Urine can be drained using a catheter until retention resolves, usually within 24 to 48 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Blood clots",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic surgery increases the risk of developing blood clots in the large veins of the leg or lung. The risk is increased for approximately six weeks after surgery. Medications may be given to some women to prevent blood clots. In addition, women taking oral contraceptives or hormone replacement should ideally discontinue them one month prior to surgery since they can further increase the risk of blood clots. Women who are sexually active and premenopausal should use alternative methods of birth control (e.g. condoms) to prevent pregnancy before surgery. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Damage to adjacent organs",
"     </span>",
"     &nbsp;&mdash;&nbsp;The urinary bladder, ureters (small tubes leading from the kidneys to the bladder), and large and small intestines are located in the lower abdomen and pelvis and can be injured during hysterectomy. Bladder injury occurs one to two percent of women who have vaginal hysterectomy, while bowel injury occurs in less than one percent of women. Injury can usually be detected and corrected at the time of surgery. If detected after surgery, another operation may be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Early menopause",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have undergone hysterectomy may experience menopause earlier than the average age of menopause (age 51). This may be due to an interruption in blood flow to the ovaries as a result of removing the uterus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      RECOVERY AFTER VAGINAL HYSTERECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     Fluids and food are generally offered soon after surgery. Intravenous (IV) fluids may be administered during the first day, particularly if there is nausea or vomiting. Pain medicine is given as needed, either intravenously, or by intramuscular (IM) injection or pill. Patients are encouraged to resume their normal daily activities as soon as possible. Being active is particularly important since it helps to prevent complications, such as blood clots, pneumonia, and gas pains.",
"    </p>",
"    <p>",
"     More information about recovery from hysterectomy is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=see_link\">",
"      \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      LIFE AFTER VAGINAL HYSTERECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     Studies of women's response to hysterectomy show that most women are very satisfied with their results (",
"     <a class=\"graphic graphic_table graphicRef68886 \" href=\"mobipreview.htm?21/12/21707\">",
"      table 1",
"     </a>",
"     ). Most reported improvement in symptoms directly related to the uterus, including pain and vaginal bleeding.",
"    </p>",
"    <p>",
"     Sexual function and enjoyment, interest in sex, and pain with sex were improved for most women. However, this improvement may be dependent upon several factors, including the age of a woman at the time of surgery, the reason for surgery, and history of any prior difficulties with mood. Younger women may grieve after hysterectomy due to their loss of fertility. A woman who has new feelings of sadness, anxiety, or depression after surgery should speak with her healthcare provider. These feelings may be treated by talking with a therapist, with antidepressant medication, or may resolve with time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      ALTERNATIVES TO HYSTERECTOMY",
"     </span>",
"    </p>",
"    <p>",
"     Some women who wish to avoid or postpone hysterectomy may use medications or less invasive surgical procedures. Medical and surgical alternatives to hysterectomy depend upon the underlying disorder. The decision as to which treatment is \"best\" should be based upon a woman's particular medical problem, all available treatment options, and the risks and benefits of each type of treatment.",
"    </p>",
"    <p>",
"     Some alternatives to vaginal hysterectomy include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Uterine artery embolization and myomectomy may be used to treat symptomatic leiomyoma (fibroids). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"        \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Pain clinics may be able to treat patients with severe and chronic pelvic pain without surgery. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/55/32627?source=see_link\">",
"        \"Patient information: Chronic pelvic pain in women (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Endometrial ablation, in which a physician destroys or removes most of the endometrium using an instrument inserted through the vagina and cervix and into the uterus. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/35/23094?source=see_link\">",
"        \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Medical therapy using hormonal medications, such GnRH analogs (for example, leuprolide) or progestins can help reduce the pain associated with endometriosis. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"        \"Patient information: Endometriosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Cone biopsy (eg, cold knife cone), cryosurgery, laser surgery, or loop electrocautery (eg, LEEP or LLETZ) are usually used to treat women with high-grade cervical intraepithelial neoplasia or carcinoma in situ of the cervix. These procedures remove the abnormal part of the cervix rather than the entire cervix and uterus (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=see_link\">",
"        \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H281\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11567388\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/41/3731?source=see_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/12/23747?source=see_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11567422\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30436?source=see_link\">",
"      Patient information: Fertility preservation in women with early stage cervical cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/4/15429?source=see_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30484?source=see_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/35/23094?source=see_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=see_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/55/32627?source=see_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=see_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link\">",
"      Abdominal hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/22/14698?source=see_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=see_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/18/35113?source=see_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12602?source=see_link\">",
"      Overview of hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29367?source=see_link\">",
"      Peripartum hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14730?source=see_link\">",
"      Radical hysterectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35401?source=see_link\">",
"      Vaginal hysterectomy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Obstetricians and Gynecologists",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acog.org/\">",
"      www.acog.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health &amp; Human Services, Federal Government Source for Women's Health Information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/\">",
"      womenshealth.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/48/34564/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/48/34564?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34564/abstract/1\">",
"      Meeks GR, Harris RL. Surgical approach to hysterectomy: abdominal, laparoscopy-assisted, or vaginal. Clin Obstet Gynecol 1997; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34564/abstract/2\">",
"      Harris WJ. Complications of hysterectomy. Clin Obstet Gynecol 1997; 40:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34564/abstract/3\">",
"      Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994; 83:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34564/abstract/4\">",
"      Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999; 282:1934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_48_34564=[""].join("\n");
var outline_f33_48_34564=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FEMALE ANATOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           REASONS FOR VAGINAL HYSTERECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PRE-OPERATIVE PLANNING AND EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           VAGINAL HYSTERECTOMY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           LAPAROSCOPICALLY ASSISTED VAGINAL HYSTERECTOMY (LAVH)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           NEED FOR ABDOMINAL HYSTERECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           VAGINAL HYSTERECTOMY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           RECOVERY AFTER VAGINAL HYSTERECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           LIFE AFTER VAGINAL HYSTERECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           ALTERNATIVES TO HYSTERECTOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/49/20243\" title=\"figure 1\">",
"           Vaginal hysterectomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\" title=\"figure 2\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/63/36851\" title=\"figure 3\">",
"           LAV hysterectomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/12/21707\" title=\"table 1\">",
"           Hysterectomy outcome PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34565="Multiple myeloma effect on vertebral bodies";
var content_f33_48_34565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple myeloma: Osteopenia, compression fracture, and lytic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The plain film of lumbar spine in the lateral projection is from a 38-year-old man with multiple myeloma. The image reveals evidence of decreased bone density, compression of L4 and T11 (yellow arrows), and lytic disease with a soft tissue mass of the posterior elements of&nbsp;L2 (red arrow).",
"    <br>",
"     (B) A correlative CT reconstruction in the sagittal projection of the thoracolumbar spine reveals multiple lytic changes in all of the visualized vertebral bodies, and reveals to better effect the destructive soft tissue process in the posterior elements of L2 (red arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Frymoyer JW, Wiesel SW, An HS, et al. The Adult and Pediatric Spine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34565=[""].join("\n");
var outline_f33_48_34565=null;
var title_f33_48_34566="Lobular carcinoma in situ of the breast";
var content_f33_48_34566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lobular carcinoma in situ of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power photomicrograph of a hematoxylin and eosin-stained section of a breast biopsy specimen from a 43-year-old woman showing classic calcifications (double-headed arrows) in an area of lobular carcinoma in situ, and similar-appearing calcifications (single arrow) in an adjacent focus of adenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: Radiologic-pathologic correlation. AJR Am J Roentgenol 2001; 176:1255. Reprinted with permission from: the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34566=[""].join("\n");
var outline_f33_48_34566=null;
var title_f33_48_34567="Treatment and prognosis of melioidosis";
var content_f33_48_34567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of melioidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Bart Currie, MBBS, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Nicholas Anstey, MBBS, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34567/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/48/34567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melioidosis is a clinically diverse disease caused by the facultative intracellular gram-negative bacterium, Burkholderia pseudomallei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This organism is a widely distributed environmental saprophyte in soil and fresh surface water in endemic regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/3\">",
"     3",
"    </a>",
"    ]; the risk of acquiring the infection occurs in these same areas.",
"   </p>",
"   <p>",
"    The treatment and prognosis of melioidosis will be presented here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39577?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cases of melioidosis, even mild disease, should be treated with initial intensive therapy (at least two weeks of intravenous therapy) followed by eradication therapy orally for a minimum of three months. B. pseudomallei are characteristically resistant to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , first- and second-generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend intensive therapy with one of the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 2 g IV every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 1 g IV every eight hours)",
"     </li>",
"     <li>",
"      Imipenem (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 1 g IV every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Ceftazidime",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    became the preferred agent for intensive therapy based upon the results of a 1989 open label randomized trial in Thailand comparing ceftazidime (120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) with a non-ceftazidime-based three drug regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [TMP-SMX; cotrimoxazole], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/7\">",
"     7",
"    </a>",
"    ]. Ceftazidime was associated with a 50 percent lower overall mortality in severe melioidosis.",
"   </p>",
"   <p>",
"    However, the trial was performed in a setting with limited intensive care resources, and intensive care therapy and possibly adjunctive therapy, such as G-CSF, is required to further reduce mortality in patients with fulminant sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mortality benefit was seen in another randomized trial of initial intensive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    in combination with TMP-SMX compared with the same non-ceftazidime-based three drug regimen in the preceding trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/11\">",
"     11",
"    </a>",
"    ]. A limitation is that the patients in the latter group were sicker at presentation. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Addition of TMP-SMX during initial intensive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    can be dosed 1 g IV every three hours or 2 g IV every six hours. Continuous ceftazidime infusions through a peripherally inserted central catheter (PICC line) have enabled early discharge for home intravenous therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. The absence of any postantibiotic effect with ceftazidime gives such a continuous infusion a theoretical advantage over intermittent dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Carbapenems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carbapenems imipenem and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    have the lowest minimum inhibitory concentrations (MIC) against B. pseudomallei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. Furthermore, in vitro time-kill studies to measure the rate of bacterial killing showed that the carbapenems perform better against B. pseudomallei than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/15\">",
"     15",
"    </a>",
"    ], including for various resistant isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, high dose imipenem was at least as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    for severe melioidosis in a randomized, comparative trial from Thailand, with no differences in mortality between the groups and with fewer treatment failures in those given imipenem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, it has been suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    may produce better outcomes in severe disease than ceftazidime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these observations, in the Northern Territory of Australia where melioidosis is hyperendemic, all patients requiring intensive care unit (ICU) admission are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    . Meropenem is used rather than imipenem because of fewer neurologic side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Addition of TMP-SMX during initial intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential advantages of combining TMP-SMX with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    are the intracellular activity of TMP-SMX and the possibility of decreasing the emergence of antimicrobial resistance with combination therapy. Emergence of resistance in B. pseudomallei during therapy has been well documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/14,15,22-26\">",
"     14,15,22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential disadvantages are antagonism between the antimicrobials and increased toxicity. Antagonism between many of the agents used for melioidosis has been demonstrated in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/5,27\">",
"     5,27",
"    </a>",
"    ], but the clinical significance of this remains uncertain. In vitro time-kill studies have shown that adding TMP-SMX had no effect on the action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the addition of TMP-SMX provides further benefit in mortality reduction compared with monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    was addressed in two randomized controlled trials of 449 patients with severe melioidosis in Thailand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/28\">",
"     28",
"    </a>",
"    ]. The two studies, although begun independently, were analyzed together as a prospective, individual-patient data meta-analysis with a primary end point of in-hospital mortality rate. The in-hospital mortality rate was not significantly different between the treatment groups (25.1 compared with 26.6 percent with combination therapy, respectively).",
"   </p>",
"   <p>",
"    The possibility that addition of TMP-SMX to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    in the intensive therapy phase might have long-term benefit was evaluated in a later report of the 190 patients with culture-confirmed melioidosis in these trials who survived to hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/29\">",
"     29",
"    </a>",
"    ]. At a median of 71 weeks, there was no difference between the two groups with regard to the combined end point of mortality or culture-confirmed recurrent melioidosis (17.8 versus 18.3 percent) with ceftazidime alone.",
"   </p>",
"   <p>",
"    Despite the lack of proven benefit, TMP-SMX is still routinely added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or a carbapenem in some centers. We do not favor routine addition of TMP-SMX to ceftazidime or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    during the initial intensive therapy phase for patients with melioidosis pneumonia or with bacteremia without an evident focus. Nevertheless, because of its excellent tissue penetration, we do favor addition of TMP-SMX in specific clinical presentations such as neurologic, prostatic, bone, joint, cutaneous, and soft tissue melioidosis. The dose of TMP-SMX used in intensive therapy is 320",
"    <span class=\"nowrap\">",
"     mg/1600",
"    </span>",
"    mg IV or PO twice daily;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (5 mg PO adult dose daily) is given to prevent or reduce the antifolate activity of TMP-SMX without affecting its antimicrobial activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial in Thailand suggested that cefoperazone-sulbactam plus TMP-SMX might be a useful alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    plus TMP-SMX for initial intensive therapy, although the number of patients in the study was inadequate for a conclusive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, others have shown that treatment failure is more common with high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    than with ceftazidime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/31\">",
"     31",
"    </a>",
"    ], and the former is generally not recommended for intensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Duration of intensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of initial intensive therapy should be at least 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/6\">",
"     6",
"    </a>",
"    ], with the Northern Territory guidelines stating at least 14 days. Four to eight weeks of intensive therapy should be administered to patients who are critically ill, have extensive pulmonary disease, deep seated collections or organ abscesses, osteomyelitis, septic arthritis, or neurologic melioidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8,32\">",
"     8,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adjunctive therapy in the intensive phase",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Abscess drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic abscesses usually require drainage since treatment failures have developed when this was not performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8,33,34\">",
"     8,33,34",
"    </a>",
"    ]. Drainage can be done under CT or portable transrectal ultrasound guidance, which can be performed in ventilated patients. Mycotic aneurysms are increasingly recognized as occurring in melioidosis and require urgent surgery, often with insertion of prosthetic vascular grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. By contrast, other internal collections frequently resolve with medical therapy and rarely need to be drained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Recombinant G-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melioidosis has been associated with functional neutrophil defects. For this reason, recombinant human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) was adopted for use in patients with septic shock due to melioidosis in the Northern Territory of Australia in December 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. A retrospective study using historical controls examined the mortality rates before and after the introduction of G-CSF therapy during the period of 1989-2002 in 42 patients with septic shock and culture-confirmed melioidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/10\">",
"     10",
"    </a>",
"    ]. Mortality in patients treated with G-CSF was dramatically lower (10 compared with 95 percent in historical controls without G-CSF therapy).",
"   </p>",
"   <p>",
"    These benefits were not confirmed in a subsequent randomized trial in Thailand in which 60",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    -treated patients with severe sepsis caused by suspected melioidosis were treated with G-CSF or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/37\">",
"     37",
"    </a>",
"    ]. Melioidosis was confirmed by culture in 18 patients given G-CSF and 23 given placebo. G-CSF therapy was associated with a nonsignificant reduction in mortality overall (70 versus 87 percent, hazard ratio 0.81, 95% CI 0.61-1.06) and in the patients with culture-proven melioidosis (83 versus 96 percent, hazard ratio 0.87, 95% CI 0.7-1.1). The duration of survival was significantly longer with G-CSF (34 versus 15 hours).",
"   </p>",
"   <p>",
"    In the observational study from Australia suggesting benefit from G-CSF, potential confounders that could have contributed to the lower mortality rate included earlier use of effective antibiotics and adoption of a closed intensive care model in the later G-CSF period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/10\">",
"     10",
"    </a>",
"    ]. On the other hand, the randomized Thailand trial was performed in a resource-limited environment (eg, no invasive monitoring, limited ventilatory and inotropic support, no dialysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Subsequent eradication therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent eradication therapy is considered necessary for preventing recrudescence or later relapse of melioidosis. This phase of treatment begins immediately after completion of initial intensive therapy. Both the choice of antibiotic and duration of eradication therapy remain uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Choice of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important trial of eradication therapy was a combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    (first four weeks only), TMP-SMX, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    versus doxycycline alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/38\">",
"     38",
"    </a>",
"    ]. Relapses were significantly higher with doxycycline alone. Similar failures of doxycycline alone as eradication therapy have been noted in the Northern Territory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/39\">",
"     39",
"    </a>",
"    ], with some B. pseudomallei relapse isolates showing acquired doxycycline resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/22\">",
"     22",
"    </a>",
"    ]. A later randomized trial in Thailand found no benefit from adding chloramphenicol to TMP-SMX plus doxycycline regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard use of TMP-SMX alone for melioidosis eradication therapy in the Northern Territory was associated with relapses being almost exclusively limited to noncompliant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8\">",
"     8",
"    </a>",
"    ]. This observation suggests that TMP-SMX is the critical component in the TMP-SMX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    regimen. Further trials in Thailand should ascertain the value of adding doxycycline to TMP-SMX alone.",
"   </p>",
"   <p>",
"    We suggest oral eradication therapy with high dose TMP-SMX (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    - 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    sulfamethoxazole up to two double-strength tablets [320",
"    <span class=\"nowrap\">",
"     mg/1600",
"    </span>",
"    mg] twice daily) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to 100 mg twice daily). As with initial intensive therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (5 mg PO adult dose daily) should be added to the TMP-SMX regimen.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    alone and oral quinolones (alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) are less effective in preventing relapse than eradication therapy with TMP-SMX and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/6,41-44\">",
"     6,41-44",
"    </a>",
"    ]. Amoxicillin-clavulanate is recommended for eradication therapy in pregnancy and in younger children if there is TMP-SMX resistance, but attention must be paid to correct recommended dosing",
"    <span class=\"nowrap\">",
"     (20/5",
"    </span>",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally three times daily) which is more than the standard amoxicillin-clavulanate dosing used for common conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/45\">",
"     45",
"    </a>",
"    ]. In vitro susceptibility testing of B. pseudomallei for quinolones generally show resistance or intermediate results, and disc diffusion techniques can give \"false-sensitive results\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/6,46\">",
"     6,46",
"    </a>",
"    ]. As a result, quinolones are NOT recommended as first-line therapy for eradication of B. pseudomallei.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest eradication therapy continue for a minimum of three months, except in patients with osteomyelitis or neurologic melioidosis, in whom eradication therapy for six months is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RISK OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular typing of isolates from recurrent melioidosis has confirmed that the majority are true relapses from failed eradication, rather than new infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/39,47-51\">",
"     39,47-51",
"    </a>",
"    ]. This was illustrated in a retrospective study of 889 Thai patients with culture-confirmed melioidosis who survived and underwent follow-up: 86 patients (9.7 percent) relapsed and 30 (3.4 percent) became reinfected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of reasons for failure of eradication therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important factor is poor compliance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/22,39,41,48\">",
"       22,39,41,48",
"      </a>",
"      ]. In the Northern Territory, we attempt to maximize compliance cases by regular follow-up during the eradication phase, with free antibiotics and action plans for defaulters, analogous to TB programs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The duration of eradication therapy is critical. Relapses after &le;8 weeks of total therapy were more likely than after more than 12 weeks of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/48,51,52\">",
"       48,51,52",
"      </a>",
"      ]. In a study from Thailand, for example, the risk of relapse was 90 percent lower in patients treated for 12 to 16 weeks compared to those treated for &le;8 weeks (HR 0.10, 95% CI 0.02-0.44) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/51\">",
"       51",
"      </a>",
"      ]. Thus, eradication therapy is recommended for 12 to 20 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/6,41\">",
"       6,41",
"      </a>",
"      ] or at least three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8,32\">",
"       8,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relapses are more common in patients with severe disease compared with those with localized melioidosis (relative risk 4.7 for severe infection in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/48\">",
"       48",
"      </a>",
"      ], emphasizing the importance of a sufficiently long duration of preceding intravenous intensive therapy. Multifocal distribution of disease and positive blood cultures have also been associated with relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of relapses usually requires reinitiation of intravenous intensive therapy, followed by eradication therapy. Surgical drainage of any persisting collections may be required and antimicrobial susceptibility testing of relapse isolates is critical to exclude acquired resistance to standard therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of asymptomatic seropositive individuals who have latent infection resulting in reactivation and disease later in life is unknown. As long as the eradication phase of therapy is completed, the prognosis is excellent in patients with non-bacteremic melioidosis. In the Northern Territory series, the mortality rate was only 4 percent in such patients compared with 37 percent in bacteremic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8\">",
"     8",
"    </a>",
"    ]. There were also no fatalities in those with chronic melioidosis (symptoms of &gt;2 months duration before diagnosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although fulminant melioidosis can occur in healthy individuals, severe disease and fatalities are uncommon in those without defined risk factors, provided there is access to appropriate antibiotics and intensive supportive care for severe sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/53\">",
"     53",
"    </a>",
"    ]. In the Northern Territory prospective melioidosis study, only 2 of the 77 fatalities amongst 540 melioidosis patients did not have an identifiable risk factor for melioidosis, and both these patients were elderly (75 and 82 years old) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/54\">",
"     54",
"    </a>",
"    ]. In that study both presence of one or more defined risk factors for melioidosis (OR 9.4) and age &ge;50 years (OR 2.0) were independent risk factors for death.",
"   </p>",
"   <p>",
"    In a randomized controlled treatment trial in Thailand, the following were identified as being independent risk factors for death and treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacteremia (odds ratio [OR] 2.9)",
"     </li>",
"     <li>",
"      Respiratory failure (OR, 6.7)",
"     </li>",
"     <li>",
"      Renal failure (OR 3.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of neurologic melioidosis is more guarded. In a series of 12 cases from the Northern Territory, five required prolonged intubation, three died, and only three made a complete recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34567/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all cases of melioidosis, even mild disease, be treated with initial intensive antimicrobial therapy followed by eradication therapy. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend intensive therapy with one of the following regimens rather than conventional therapy. (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial intensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 2 g IV every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 1 g IV every eight hours)",
"     </li>",
"     <li>",
"      Imipenem (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 1 g IV every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal duration of intensive therapy has not been studied; we recommend treatment for at least two weeks. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Duration of intensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive therapy in the intensive therapy phase may include drainage for prostatic abscesses and intensive care. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adjunctive therapy in the intensive phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest G-CSF administration for patients in septic shock (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Recombinant G-CSF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend oral eradication therapy be initiated immediately following initial intensive therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Subsequent eradication therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest eradication therapy with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      - 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      sulfamethoxazole up to two double-strength tablets [320",
"      <span class=\"nowrap\">",
"       mg/1600",
"      </span>",
"      mg] twice daily) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      (5 mg oral adult dose daily) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Oral therapy is continued for a minimum of three months. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Subsequent eradication therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/1\">",
"      White NJ. Melioidosis. Lancet 2003; 361:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/2\">",
"      Currie BJ. Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. Eur Respir J 2003; 22:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/3\">",
"      Dance DA. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop 2000; 74:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/4\">",
"      Leelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis 1989; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/5\">",
"      Eickhoff TC, Bennett JV, Hayes PS, Feeley J. Pseudomonas pseudomallei: susceptibility to chemotherapeutic agents. J Infect Dis 1970; 121:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/6\">",
"      Chaowagul W. Recent advances in the treatment of severe melioidosis. Acta Trop 2000; 74:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/7\">",
"      White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/8\">",
"      Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/9\">",
"      Cheng AC, Lowe M, Stephens DP, Currie BJ. Ethical problems of evaluating a new treatment for melioidosis. BMJ 2003; 327:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/10\">",
"      Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/11\">",
"      Sookpranee M, Boonma P, Susaengrat W, et al. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992; 36:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/12\">",
"      Huffam S, Jacups SP, Kittler P, Currie BJ. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters. Trop Med Int Health 2004; 9:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/13\">",
"      Walsh AL, Smith MD, Wuthiekanun V, White NJ. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment. Antimicrob Agents Chemother 1995; 39:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/14\">",
"      Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 1989; 24:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/15\">",
"      Smith MD, Wuthiekanun V, Walsh AL, White NJ. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994; 33:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/16\">",
"      Ashdown LR. In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Antimicrob Agents Chemother 1988; 32:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/17\">",
"      McEniry DW, Gillespie SH, Felmingham D. Susceptibility of Pseudomonas pseudomallei to new beta-lactam and aminoglycoside antibiotics. J Antimicrob Chemother 1988; 21:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/18\">",
"      Yamamoto T, Naigowit P, Dejsirilert S, et al. In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob Agents Chemother 1990; 34:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/19\">",
"      Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 1996; 37:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/20\">",
"      Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/21\">",
"      Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004; 48:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/22\">",
"      Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 2001; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/23\">",
"      Dance DA, Wuthiekanun V, White NJ, Chaowagul W. Antibiotic resistance in Pseudomonas pseudomallei. Lancet 1988; 1:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/24\">",
"      Godfrey AJ, Wong S, Dance DA, et al. Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase. Antimicrob Agents Chemother 1991; 35:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/25\">",
"      Dance DA, Wuthiekanun V, Chaowagul W, et al. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J Antimicrob Chemother 1991; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/26\">",
"      Toohey M, Lew AE, Desmarchelier PM. Laboratory investigations of Australian isolates of ceftazidime resistant Pseudomonas pseudomallei. Antibiotic Special Interest Group (Australian Society of Microbiology) Newsletter 1994; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/27\">",
"      Dance DA, Wuthiekanun V, Chaowagul W, White NJ. Interactions in vitro between agents used to treat melioidosis. J Antimicrob Chemother 1989; 24:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/28\">",
"      Chierakul W, Anunnatsiri S, Short JM, et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005; 41:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/29\">",
"      Chierakul W, Anunnatsiri S, Chaowagul W, et al. Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit. Clin Infect Dis 2007; 45:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/30\">",
"      Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J Med Assoc Thai 1998; 81:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/31\">",
"      Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19:846.",
"     </a>",
"    </li>",
"    <li>",
"     Writing Group: Melioidosis. In: Therapeutic Guidelines: Antibiotic, 14th ed, Therapeutic Guidelines Ltd, North Melbourne, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/33\">",
"      Demar M, Ferroni A, Dupont B, et al. Suppurative epididymo-orchitis and chronic prostatitis caused by Burkholderia pseudomallei: a case report and review. J Travel Med 2005; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/34\">",
"      Morse LP, Moller CC, Harvey E, et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol 2009; 182:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/35\">",
"      Low JG, Quek AM, Sin YK, Ang BS. Mycotic aneurysm due to Burkholderia pseudomallei infection: case reports and literature review. Clin Infect Dis 2005; 40:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/36\">",
"      Amezyane T, Lecoules S, Algayres JP. Mycotic iliac aneurysm associated with Burkholderia pseudomallei. Int J Infect Dis 2010; 14 Suppl 3:e381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/37\">",
"      Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007; 45:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/38\">",
"      Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis 1999; 29:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/39\">",
"      Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 2000; 94:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/40\">",
"      Chaowagul W, Chierakul W, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005; 49:4020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/41\">",
"      Rajchanuvong A, Chaowagul W, Suputtamongkol Y, et al. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1995; 89:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/42\">",
"      Chaowagul W, Suputtamongkul Y, Smith MD, White NJ. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1997; 91:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/43\">",
"      Chetchotisakd P, Chaowagul W, Mootsikapun P, et al. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am J Trop Med Hyg 2001; 64:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/44\">",
"      Ashdown LR, Currie BJ. Melioidosis: when in doubt leave the quinolone alone! Med J Aust 1992; 157:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/45\">",
"      Cheng AC, Chierakul W, Chaowagul W, et al. Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. Am J Trop Med Hyg 2008; 78:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/46\">",
"      Chau PY, Ng WS, Leung YK, Lolekha S. In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer beta-lactam antibiotics and quinolone derivatives. J Infect Dis 1986; 153:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/47\">",
"      Desmarchelier PM, Dance DA, Chaowagul W, et al. Relationships among Pseudomonas pseudomallei isolates from patients with recurrent melioidosis. J Clin Microbiol 1993; 31:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/48\">",
"      Chaowagul W, Suputtamongkol Y, Dance DA, et al. Relapse in melioidosis: incidence and risk factors. J Infect Dis 1993; 168:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/49\">",
"      Haase A, Melder A, Smith-Vaughan H, et al. RAPD analysis of isolates of Burkholderia pseudomallei from patients with recurrent melioidosis. Epidemiol Infect 1995; 115:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/50\">",
"      Mohandas S, Puthucheary S, Pang T. Relapsing infection due to Burkholderia pseudomallei detected by pulsed-field gel electrophoresis of sequential clinical isolates. Asian Pac J Mol Biol 1995; 3:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/51\">",
"      Limmathurotsakul D, Chaowagul W, Chierakul W, et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis 2006; 43:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/52\">",
"      Suputtamongkol Y, Dance DA, Chaowagul W, et al. Amoxycillin-clavulanic acid treatment of melioidosis. Trans R Soc Trop Med Hyg 1991; 85:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/53\">",
"      Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med 2008; 5:e175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/54\">",
"      Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:e900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34567/abstract/55\">",
"      Currie BJ, Fisher DA, Howard DM, Burrow JN. Neurological melioidosis. Acta Trop 2000; 74:145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3136 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34567=[""].join("\n");
var outline_f33_48_34567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Ceftazidime",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Carbapenems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Addition of TMP-SMX during initial intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Duration of intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adjunctive therapy in the intensive phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Abscess drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Recombinant G-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Subsequent eradication therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Choice of agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RISK OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39577?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34568="Cyclic vomiting syndrome";
var content_f33_48_34568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cyclic vomiting syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Emily Dulude, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     David J Desilets, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Richard G Boles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34568/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/48/34568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic vomiting syndrome (CVS) is an idiopathic disorder characterized by recurrent, stereotypical bouts of vomiting with intervening periods of normal health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/1\">",
"     1",
"    </a>",
"    ]. Although it appears to primarily affect children, it is being recognized increasingly in adults.",
"   </p>",
"   <p>",
"    CVS was first described in France in 1861 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/2\">",
"     2",
"    </a>",
"    ]. The first English-language publication, in 1882, described three essential clinical features of the disorder, which still hold true today [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three or more recurrent discrete episodes of vomiting",
"     </li>",
"     <li>",
"      Varying intervals of completely normal health between episodes",
"     </li>",
"     <li>",
"      Episodes are stereotypical with regard to timing of onset, symptoms, and duration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A critical fourth criterion that has been added subsequently includes the absence of an organic cause of vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of cyclic vomiting syndrome in adults and children. A guideline on this topic has also been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic vomiting syndrome (CVS) is no longer considered to be rare in children. A cross-sectional study of school-age children in Aberdeen, Scotland, estimated that 34 of 2165 children (1.6 percent) fulfilled the diagnostic criteria for CVS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/5\">",
"     5",
"    </a>",
"    ]. Their average age was 9.6 years at the time of diagnosis, while the average age at the onset of symptoms was 5.3 years. The overall gender ratio was equal, although, among younger children, it was more common in boys. A similar age distribution has been described in other reports of children, although many have suggested that it may be more common in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4,6-10\">",
"     4,6-10",
"    </a>",
"    ]. A family in which CVS appears to be inherited has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder appears to be less common in adults, although there are no population-based studies from which estimates of its prevalence can be devised. One of the largest studies, which included 17 adult patients seen during a 10-year period at an academic medical center, found that the CVS began at an average age of 35 (range 14 to 73 years) but was not diagnosed until patients were on average 41 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ]. The gender distribution was equal. The average length of episodes was six days (range 1 to 21 days), with symptom-free intervals averaging three months (range 0.5 to 6 months). Similar findings have been described in other reports in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there appear to be similarities in CVS across age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/7\">",
"     7",
"    </a>",
"    ], a few differences between adults and children have been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults have on average approximately four cycles per year in contrast with 12 cycles per year in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The age of onset covers a broad span in adults, while in children the age of onset is often in the toddler or preschool years.",
"     </li>",
"     <li>",
"      Adults have usually been symptomatic for longer prior to diagnosis, possibly reflecting the increased recognition of CVS by pediatricians.",
"     </li>",
"     <li>",
"      Triggering events are less common in adults.",
"     </li>",
"     <li>",
"      Nausea between episodes is more common in adults.",
"     </li>",
"     <li>",
"      CVS in children, but not in adults, is highly associated with two common mitochondrial DNA polymorphisms, 16519T and 3010A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of cyclic vomiting syndrome (CVS) remains unknown, although it may represent a heterogeneous group of disorders. An association between CVS and migraine headaches has been most consistently described, suggesting that there may be a common pathophysiologic process. However, CVS has also been linked to food allergy, mitochondrial, metabolic, and endocrine disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CVS and migraines",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVS has been linked to migraine headaches and abdominal migraine (",
"    <a class=\"graphic graphic_table graphicRef80667 \" href=\"mobipreview.htm?12/40/12940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This connection is based upon the discreteness of episodes, the progression from cyclic vomiting to migraine headaches in many patients, the presence of a strong family history of migraine headaches in affected children (approximately 80 percent), and the response to antimigraine therapy in up to 80 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. Sympathetic autonomic dysfunction may predispose children to both CVS and migraine headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8600?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One hypothesis is that CVS may lead to abdominal migraines, which in turn lead to migraine headaches. However, more children progress directly from CVS to migraines than from CVS to abdominal migraines to migraines. Abdominal migraines can be distinguished from CVS in that the core symptom of abdominal migraines is abdominal pain, not vomiting. Both syndromes may have headache as a feature and respond to antimigraine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial disorders of fatty acid oxidation (eg, medium-chain acyl coenzyme A dehydrogenase deficiency), respiratory chain defects (eg, MELAS: Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Syndrome), and mitochondrial DNA deletions can be associated with episodes of metabolic crisis and vomiting, usually with infection or prolonged fasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37433?source=see_link\">",
"     \"Overview of the hereditary ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One group suggested that about one-half of patients with cyclic vomiting syndrome have evidence for maternal inheritance of a mitochondrial DNA sequence variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared with controls, mothers of patients with cyclic vomiting syndrome were more likely to have a history of migraine, depression, irritable bowel syndrome, and hypothyroidism, disorders that the researchers hypothesized may segregate with cyclic vomiting syndrome in families due to predisposing mitochondrial DNA sequence variants. The authors speculated that cyclic vomiting syndrome represents a rare clinical presentation in individuals who carry the predisposing mitochondrial variants that are more commonly associated with migraine, depression, irritable bowel syndrome, hypothyroidism, and other",
"    <span class=\"nowrap\">",
"     functional/dysautonomic",
"    </span>",
"    conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The efficacy of mitochondrial-targeted therapies, co-enzyme Q10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27,29\">",
"     27,29",
"    </a>",
"    ], in CVS strengthens the hypothesis of a",
"    <span class=\"nowrap\">",
"     metabolic/mitochondrial",
"    </span>",
"    component in disease pathogenesis. This hypothesis is further strengthened by an association of both CVS and migraine headache with the same two mitochondrial DNA polymorphisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dysautonomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a hereditary sensory autonomic neuropathy (such as Riley Day Syndrome) can also have clinical features resembling CVS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypothalamic-pituitary-adrenal axis defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated corticotropin, cortisol, vasopressin, prostaglandin E2, and catecholamines have been described in a group of children with cyclic vomiting, profound lethargy, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/31\">",
"     31",
"    </a>",
"    ]. Animal studies suggest that CVS may be a brain-gut disorder in which corticotropin-releasing factor induces gastric stasis and vomiting by vagal stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Food allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitivity to cow's milk, soy, and egg white protein may be related to CVS in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/6\">",
"     6",
"    </a>",
"    ]. Other food triggers include chocolate, cheese, and monosodium glutamate. The relationship between food allergy and CVS is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Catamenial CVS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to menstrual migraine headaches, some girls develop catamenial CVS at the onset of their menstrual period. Some respond to treatment with a low-dose estrogen or progesterone-only birth control pill, although oral contraceptives and other steroids can also precipitate vomiting episodes and other symptomatology in some. An association between symptoms and menses has also been described in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic cannabis use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cessation of chronic cannabis use has been associated with resolution of persistent vomiting in case reports suggesting a causal association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. In one series, the association was characterized by repetitive washing behavior during vomiting cycles, which is not a feature of CVS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/33\">",
"     33",
"    </a>",
"    ]. Also, patients with \"cannabis hyperemesis syndrome\" vomit daily, without the periods of completely normal health required as one of the essential features of CVS described above (see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above). However, many adults with CVS self-medicate with cannabis to alleviate their nausea, and this can be a source of diagnostic confusion. In general, patients who use cannabis most days, and who exhibit frequent",
"    <span class=\"nowrap\">",
"     bathing/showering",
"    </span>",
"    behavior, are most likely to have &ldquo;cannabis hyperemesis syndrome&rdquo; and not CVS. CVS cannot be diagnosed until patients abstain from cannabis for at least one to two weeks; if the emesis continues, then further work-up for CVS can be undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the proposed diagnostic criteria suggests two essential features of cyclic vomiting syndrome (CVS). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stereotypical episodes of vomiting regarding onset (acute) and duration (hours to days)",
"     </li>",
"     <li>",
"      The absence of nausea and vomiting between episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria for the diagnosis of CVS include a history or family history of migraine headaches, the self-limited nature of the attacks, associated symptoms of nausea, abdominal pain, headache, motion sickness, photophobia, and lethargy, and associated signs of fever, pallor, diarrhea, dehydration, excess salivation, and social withdrawal. In children, nausea and possibly lethargy are considered to be key diagnostic features.",
"   </p>",
"   <p>",
"    The specific pattern of vomiting episodes is variable among patients but, importantly, is stereotypical for an individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/37\">",
"     37",
"    </a>",
"    ]. In general, CVS episodes tend to begin in the early morning hours (2:00 to 7:00 AM) and may involve a prodromal period of pallor, anorexia, nausea, abdominal pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lethargy (",
"    <a class=\"graphic graphic_table graphicRef62483 \" href=\"mobipreview.htm?19/3/19516\">",
"     table 2",
"    </a>",
"    ). In children, the attacks last an average of 24 to 48 hours. Approximately one-half of children have attacks at regular intervals, commonly occurring every two to four weeks, while the others have an unpredictable temporal pattern of vomiting. Approximately two-thirds of parents can identify a trigger, which is usually infectious (upper respiratory) or psychological (negative or positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, episodes tend to be longer in adults (approximately three to six days) with longer intervening intervals of normal health (approximately three months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Intervening episodes of normal health are important for distinguishing CVS from functional nausea and vomiting in which symptoms are present continuously or nearly continuously (",
"    <a class=\"graphic graphic_figure graphicRef54863 \" href=\"mobipreview.htm?37/41/38557\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The characteristics on presentation (and difficulty establishing the diagnosis) were illustrated in a group of 17 adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each patient had been evaluated by at least two physicians (typically with repeated imaging and endoscopic studies) and had been hospitalized at least once. Three patients (18 percent) required nutritional support.",
"     </li>",
"     <li>",
"      Three patients had undergone surgical exploration and partial gastrectomy, pyloroplasty, or fundoplication without improvement.",
"     </li>",
"     <li>",
"      Abdominal pain was present during episodes in approximately two-thirds of patients.",
"     </li>",
"     <li>",
"      Only 20 percent of patients had a psychiatric diagnosis (either anxiety or another affective disorder).",
"     </li>",
"     <li>",
"      Erosive esophagitis was observed in 50 percent of patients during or shortly after a vomiting episode (including one patient who had a Mallory-Weiss tear). However, in no patients did vomiting episodes improve with antireflux measures.",
"     </li>",
"     <li>",
"      Only one-third of patients described a prodrome of nausea, epigastric pain, or both, while the others reported the onset of symptoms without warning.",
"     </li>",
"     <li>",
"      Four of seven reproductive age women described a link to their menstrual cycle; two had severe episodes precipitated by pregnancy.",
"     </li>",
"     <li>",
"      Sleep was beneficial in relieving symptoms in four patients (23 percent).",
"     </li>",
"     <li>",
"      A history of migraine headaches was described in only four patients (23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children outgrow cyclic vomiting syndrome (CVS) by their preteen or early teenage years. However, some authors have observed that up to 75 percent of children with CVS will go on to develop migraine headaches by age 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/19\">",
"     19",
"    </a>",
"    ]. A minority of children who progress from CVS to migraine headaches will first pass through a phase of abdominal migraines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/39\">",
"     39",
"    </a>",
"    ]. One retrospective study of 51 children followed for up to 13 years found that vomiting resolved in 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/40\">",
"     40",
"    </a>",
"    ]. However, 42 percent continued to have regular headaches and 37 percent had abdominal pain; these features were present even in patients whose vomiting had resolved.",
"   </p>",
"   <p>",
"    The natural history in adults has not been well studied. In the series of 17 adults described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ], 13 had at least a partial response to antidepressant therapy while an additional 3 responded to other types of treatment. One patient had persistent symptoms during two years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic vomiting syndrome (CVS) remains a diagnosis based upon the history and exclusion of alternative diagnoses (",
"    <a class=\"graphic graphic_table graphicRef57659 \" href=\"mobipreview.htm?4/40/4751\">",
"     table 3",
"    </a>",
"    ). At least two sets of criteria have been proposed based upon a consensus of experts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rome III criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rome III criteria include the presence of all of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stereotypical episodes of vomiting regarding onset (acute) and duration (less than one week)",
"     </li>",
"     <li>",
"      Three or more discrete episodes in the prior year",
"     </li>",
"     <li>",
"      Absence of nausea and vomiting between episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"   </p>",
"   <p>",
"    Supportive criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History or family history of migraine headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     North American Society for Pediatric Gastroenterology Hepatology and Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus statement issued by the North American Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) suggests the following diagnostic criteria (all of which must be met) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"     4",
"    </a>",
"    ]. These recommendations apply to children and adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At least five attacks in any interval, or a minimum of three attacks during a six-month period",
"     </li>",
"     <li>",
"      Episodic attacks of intense nausea and vomiting lasting 1 hour to 10 days and occurring at least one week apart",
"     </li>",
"     <li>",
"      Stereotypical pattern and symptoms in the individual patient",
"     </li>",
"     <li>",
"      Vomiting during attacks occurs at least four times per hour for at least one hour",
"     </li>",
"     <li>",
"      Return to baseline health between episodes",
"     </li>",
"     <li>",
"      Not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendations for diagnosis and treatment from NASPGHAN (which apply to children and adolescents) are summarized in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef53337 \" href=\"mobipreview.htm?32/6/32867\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77478 graphicRef68579 graphicRef78562 graphicRef59920 \" href=\"mobipreview.htm?18/3/18495\">",
"     table 4A-D",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Warning signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Warning signs alerting to an alternative diagnosis include the presence of severe headaches, altered mental status, gait disturbances or other new \"neurological signs\", gastrointestinal bleeding, unilateral abdominal pain, weight loss, failure to respond to treatment, progressive worsening, prolonged episodes requiring hospitalization, and a change in pattern or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"     4",
"    </a>",
"    ]. An upper gastrointestinal series should be performed in children to exclude intestinal malrotation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=see_link\">",
"     \"Intestinal malrotation\"",
"    </a>",
"    .) Ureteropelvic junction obstruction has been reported to be an overlooked mimic of CVS in a case series of four children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/42\">",
"     42",
"    </a>",
"    ]. CVS should be considered among other diagnoses in patients presenting with nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24521?source=see_link\">",
"     \"Approach to the infant or child with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach to excluding other disorders of recurrent vomiting includes a complete, extensive evaluation of standard blood work (electrolytes, glucose, ALT, GGTP, amylase, lipase), urinalysis, and (in children) evaluation for metabolic disorders (eg, lactate, ammonia, amino acids, urine organic acids) during an acute episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24521?source=see_link\">",
"     \"Approach to the infant or child with nausea and vomiting\"",
"    </a>",
"    .) Patients should also be asked about frequent bathing behavior. If present, this can be used as a springboard to probe deeper into the possibility of chronic cannabis use and &ldquo;cannabis hyperemesis syndrome&rdquo;. An upper gastrointestinal series with small bowel follow-through X-ray",
"    <span class=\"nowrap\">",
"     (UGI/SBFT),",
"    </span>",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    of the head, and endoscopy can be performed between episodes. As noted above, the presence of esophagitis on endoscopy (performed during or near an episode) does not necessarily imply that reflux is an underlying cause, since as many as one-half of patients will have esophagitis but will not respond to antireflux measures.",
"   </p>",
"   <p>",
"    Only one in eight children with cyclical episodes of vomiting who were evaluated with this approach has been found to have another underlying disorder that required intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the cost of initial diagnostic testing and annual ambulatory and hospital treatment of CVS using the above approach was estimated to be $17,035 per child in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/22\">",
"     22",
"    </a>",
"    ]. A decision-analysis concluded that a more cost-effective diagnostic strategy in children was to obtain a",
"    <span class=\"nowrap\">",
"     UGI/SBFT",
"    </span>",
"    to rule out malrotation with volvulus, followed by a two-month trial of antimigraine therapy, with further studies reserved for those with continued symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/43\">",
"     43",
"    </a>",
"    ]. In adults, a CT scan of the abdomen and pelvis has been suggested to exclude malignancy and other structural disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may require supportive care during severe bouts of cyclic vomiting, which may include admission to a hospital, intravenous fluids, antiemetics, and occasionally analgesics. Children should be referred to a pediatric gastroenterologist, neurologist, or metabolic specialist. Recognized precipitating factors (more commonly observed in children) should be avoided whenever feasible. Examples include physical exhaustion, motion (car rides, amusement park rides), fasting, and certain foods (eg, chocolate, cheese).",
"   </p>",
"   <p>",
"    No specific therapy has been proven to be effective for cyclic vomiting syndrome (CVS) in controlled trials. However, several empiric treatments have been effective in case series. Treatment with medications should be guided by three considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whether there is a family history of migraines",
"     </li>",
"     <li>",
"      Frequency of episodes",
"     </li>",
"     <li>",
"      Severity of episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment can also be considered as abortive, prophylactic, and supportive.",
"   </p>",
"   <p>",
"    A trial of antimigraine medications is reasonable in patients with a family history of migraine headaches. Some authors recommend antimigraine therapy even in the absence of a personal or family history of migraines if, after careful evaluation, the diagnosis of CVS seems certain.",
"   </p>",
"   <p>",
"    The decision to administer abortive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prophylactic antimigraine medications depends upon the frequency and severity of the attacks, similar to the principles that guide treatment of patients with migraine headaches. Prophylactic daily therapy with antimigraine medications is warranted if attacks occur more than once every one to two months or are severe enough to require hospitalization or substantial disability. In contrast, abortive therapy can be used if episodes occur less than once every one to two months or are mild. The choice of specific agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18490?source=see_link\">",
"     \"Management of migraine headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents that have been used empirically (with variable success) in children include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , coenzyme Q10,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    , and tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27-29,44,45\">",
"     27-29,44,45",
"    </a>",
"    ]. Some authorities advocate use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for prophylaxis in children older than five even if there is no history of headache or a family history of migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/26\">",
"     26",
"    </a>",
"    ]. A common starting dose is 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day at bedtime, although many patients require a higher dose, often 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day at bedtime. It typically takes one to three months for the effects of amitriptyline to become evident.",
"   </p>",
"   <p>",
"    Some CVS patients who do not respond to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day have very low or undetectable blood levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and respond when the amitriptyline dosage is further increased. Many patients do not respond until the blood amitriptyline plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    level exceeds 150",
"    <span class=\"nowrap\">",
"     micrograms/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/28\">",
"     28",
"    </a>",
"    ]. As a general rule, a blood amitriptyline level should be obtained before attempting to exceed 1",
"    <span class=\"nowrap\">",
"     mg/kg/",
"    </span>",
"    per day to avoid a toxic level.",
"   </p>",
"   <p>",
"    Retrospective studies have demonstrated substantial efficacy of the dietary supplements coenzyme Q10 and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. These supplements can be purchased over-the-counter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by prescription, which varies by location. The efficacy of coenzyme Q10 may be as great as that for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27\">",
"     27",
"    </a>",
"    ]. One article presented a protocol that was 90 percent effective in substantially reducing vomiting episodes by combining these supplements with amitriptyline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/28\">",
"     28",
"    </a>",
"    ]. A common starting dose for coenzyme Q10 is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or 200 mg twice daily. A common starting dose for L-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is 50 or 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or one gram twice daily. Many patients require higher dosages, and suggested blood levels were &gt;3.0",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    for coenzyme Q10, and a free carnitine level &gt;40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    may be limited in infants and toddlers under 5 years of age due to side effects (such as personality changes, anticholinergic effects, and tachyarrhythmias). The EKG (particularly the QTc interval) and electrolytes (K+, Mag+) should be monitored.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"     Cyproheptadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are often used as alternatives. Cyproheptadine is recommended as first-line treatment in children under age five years. Therapies of unproven efficacy that have been used include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and riboflavin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/38/5736?source=see_link\">",
"     Sumatriptan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , and tricyclic antidepressants have been used in case reports in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/13,45-47\">",
"     13,45-47",
"    </a>",
"    ]. Low-dose estrogen or progesterone-only birth control pills can be used as directed in females with catamenial CVS in whom vomiting attacks occur at the time of menses; however, birth control pills can also exacerbate symptoms in CVS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4,48\">",
"     4,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=see_link\">",
"     \"Estrogen-associated migraine\"",
"    </a>",
"    .) A variety of antiemetic medications have been used unsuccessfully, including high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinical response to tricyclic antidepressants was observed in 13 of 17 adults in the report described above (although only three patients had a complete response) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"     12",
"    </a>",
"    ]. Antidepressants used included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    (median dose for each is 50 mg daily). Two other patients responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    . Another report described improvement with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    (antiepileptic drugs) in adults who had symptoms refractory to tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/49\">",
"     49",
"    </a>",
"    ]. However, side-effects (such as fatigue, confusion, headache, and poor concentration) were common.",
"   </p>",
"   <p>",
"    During vomiting episodes, the goal is to abort or shorten the episode. Anecdotal experience in children suggests that intravenous administration of a 10 percent dextrose solution can decrease the frequency and duration of vomiting episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/26\">",
"     26",
"    </a>",
"    ] in about one-half of patients. Between episodes, frequent low fat feedings have been advocated to decrease the frequency of episodes. These observations may have a pathophysiologic basis in the impaired carbohydrate and fat metabolism that has been described in children with mitochondrial variants that may predispose to cyclic vomiting syndrome. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Metabolic disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to 10 percent intravenous dextrose, anecdotal experience suggests that high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    (0.3 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg/dose,",
"    </span>",
"    maximum about 20",
"    <span class=\"nowrap\">",
"     mg/dose),",
"    </span>",
"    sedation (eg, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ), and a quiet, dark room are often helpful. Drinking water to induce vomiting (and thus lessening nausea) is common, and does not indicate a factitious or psychiatric etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34568/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support and counseling may be helpful for selected patients. The Cyclic Vomiting Syndrome Association (CVSA), an international organization, was established in 1993 to provide support to patients with CVS.",
"   </p>",
"   <p>",
"    For more information on the CVSA, contact:",
"   </p>",
"   <p>",
"    Cyclic Vomiting Syndrome Association",
"    <span class=\"nowrap\">",
"     (CVSA-USA/Canada)",
"    </span>",
"   </p>",
"   <p>",
"    2819 West Highland Blvd.",
"   </p>",
"   <p>",
"    Milwaukee, WI 53208",
"   </p>",
"   <p>",
"    Phone: 414-342-7880",
"   </p>",
"   <p>",
"    Fax: 414-342-8980",
"   </p>",
"   <p>",
"    E-mail: cvsa@cvsaonline.org",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://www.cvsaonline.org/\">",
"     www.cvsaonline.org",
"    </a>",
"   </p>",
"   <p>",
"    Additional resources that might be useful are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef74868 \" href=\"mobipreview.htm?10/46/10988\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyclic vomiting syndrome (CVS) is an idiopathic disorder characterized by recurrent, stereotypical bouts of vomiting with intervening periods of normal health. Although it appears to affect primarily children, it is being recognized increasingly in adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of CVS remains unknown, although it may represent a heterogeneous group of disorders. An association between CVS and migraine headaches has been most consistently described, suggesting that there may be a common pathophysiologic process. However, CVS has also been linked to food allergy, mitochondrial, metabolic, and endocrine disorders. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic criteria have been proposed based upon consensus of experts. The specific pattern of vomiting is variable among patients but, importantly, is stereotypical for an individual patient. Cyclic vomiting syndrome remains a diagnosis based upon the history and exclusion of alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment can be considered as abortive, prophylactic, and supportive. Most treatments have been based upon observational data or clinical experience, forming the basis for the following suggested approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      If episodes occur more often than monthly, or if they are prolonged or debilitating, daily prophylactic therapy is recommended. If episodes are less frequent or are mild, abortive therapy at the onset of episodes is often preferred. If abortive therapy fails after two or three attempts, then switch to prophylactic therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18490?source=see_link\">",
"       \"Management of migraine headache in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"       \"Acute treatment of migraine in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link\">",
"       \"Preventive treatment of migraine in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some authorities advocate use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day increased as needed to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or higher per day at bedtime, aim for a blood level of 150 to 200",
"      <span class=\"nowrap\">",
"       micrograms/L)",
"      </span>",
"      for prophylaxis even if there is no history of headache or a family history of migraine. However, its use may be limited due to side effects in infants and toddlers under age five years. The EKG (particularly the QTc interval) should be monitored. In children under age five years,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"       cyproheptadine",
"      </a>",
"      is the first choice (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/15/40181?source=see_link\">",
"       pizotifen",
"      </a>",
"      outside of the United States).",
"      <br/>",
"      <br/>",
"      Coenzyme Q10 (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, or 200 mg twice daily) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      (50 or 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, or one gram twice daily) have been advocated in prophylaxis, as data suggest that these dietary supplements may be highly effective, and side effects are infrequent and mild.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      is an unproven therapy that is gaining in popularity due to anecdotal experiences of efficacy, although side effects are frequent and often significant. Abortive therapy with intravenous dextrose (10 percent) and high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      (0.3 to 0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, or 12 to 16",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      have been found to be helpful in anecdotal reports in children. Comfort measures during episodes include a dark quiet room, and sedation as appropriate. In addition, patients should be instructed to avoid fasting.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/1\">",
"      Li BU. Cyclic vomiting syndrome: light emerging from the black box. J Pediatr 1999; 135:276.",
"     </a>",
"    </li>",
"    <li>",
"     Lombard HC. Evrose de la digestion, caracteriseo par des crises periodiques de vomissements et une profonde modification de l'assimilation. Gazette Medicale de Paris 1861:312.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/3\">",
"      Gee S. On fitful or recurrent vomiting. St Bartholomew Hospital Reports 1882; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/4\">",
"      Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/5\">",
"      Abu-Arafeh I, Russell G. Cyclical vomiting syndrome in children: a population-based study. J Pediatr Gastroenterol Nutr 1995; 21:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/6\">",
"      Lucarelli S, Corrado G, Pelliccia A, et al. Cyclic vomiting syndrome and food allergy/intolerance in seven children: a possible association. Eur J Pediatr 2000; 159:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/7\">",
"      Prakash C, Staiano A, Rothbaum RJ, Clouse RE. Similarities in cyclic vomiting syndrome across age groups. Am J Gastroenterol 2001; 96:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/8\">",
"      Withers GD, Silburn SR, Forbes DA. Precipitants and aetiology of cyclic vomiting syndrome. Acta Paediatr 1998; 87:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/9\">",
"      HOYT CS, STICKLER GB. A study of 44 children with the syndrome of recurrent (cyclic) vomiting. Pediatrics 1960; 25:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/10\">",
"      Lee WS, Kaur P, Boey CC, Chan KC. Cyclic vomiting syndrome in South-East Asian children. J Paediatr Child Health 1998; 34:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/11\">",
"      Haan J, Kors EE, Ferrari MD. Familial cyclic vomiting syndrome. Cephalalgia 2002; 22:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/12\">",
"      Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 1999; 94:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/13\">",
"      Scobie BA. Recurrent vomiting in adults. A syndrome? Med J Aust 1983; 1:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/14\">",
"      Abell TL, Kim CH, Malagelada JR. Idiopathic cyclic nausea and vomiting--a disorder of gastrointestinal motility? Mayo Clin Proc 1988; 63:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/15\">",
"      Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr 1993; 17:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/16\">",
"      Boles RG, Zaki EA, Lavenbarg T, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil 2009; 21:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/17\">",
"      Welch KM. Scientific basis of migraine: speculation on the relationship to cyclic vomiting. Dig Dis Sci 1999; 44:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/18\">",
"      Jernigan SA, Ware LM. Reversible quantitative EEG changes in a case of cyclic vomiting: evidence for migraine equivalent. Dev Med Child Neurol 1991; 33:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/19\">",
"      Li BU, Murray RD, Heitlinger LA, et al. Is cyclic vomiting syndrome related to migraine? J Pediatr 1999; 134:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/20\">",
"      To J, Issenman RM, Kamath MV. Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability. J Pediatr 1999; 135:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/21\">",
"      Chelimsky TC, Chelimsky GG. Autonomic abnormalities in cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2007; 44:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/22\">",
"      Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/23\">",
"      Boles RG, Chun N, Senadheera D, Wong LJ. Cyclic vomiting syndrome and mitochondrial DNA mutations. Lancet 1997; 350:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/24\">",
"      Boles RG, Adams K, Li BU. Maternal inheritance in cyclic vomiting syndrome. Am J Med Genet A 2005; 133A:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/25\">",
"      Wang Q, Ito M, Adams K, et al. Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. Am J Med Genet A 2004; 131:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/26\">",
"      Boles RG, Adams K, Ito M, Li BU. Maternal inheritance in cyclic vomiting syndrome with neuromuscular disease. Am J Med Genet A 2003; 120A:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/27\">",
"      Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010; 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/28\">",
"      Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. BMC Neurol 2011; 11:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/29\">",
"      Van Calcar SC, Harding CO, Wolff JA. L-carnitine administration reduces number of episodes in cyclic vomiting syndrome. Clin Pediatr (Phila) 2002; 41:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/30\">",
"      Zaki EA, Freilinger T, Klopstock T, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia 2009; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/31\">",
"      Sato T, Igarashi N, Minami S, et al. Recurrent attacks of vomiting, hypertension and psychotic depression: a syndrome of periodic catecholamine and prostaglandin discharge. Acta Endocrinol (Copenh) 1988; 117:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/32\">",
"      Tach&eacute; Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci 1999; 44:79S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/33\">",
"      Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/34\">",
"      Roche E, Foster PN. Cannabinoid hyperemesis: not just a problem in Adelaide Hills. Gut 2005; 54:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/35\">",
"      Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol 2009; 15:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/36\">",
"      Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 2012; 87:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/37\">",
"      Fleisher DR, Gornowicz B, Adams K, et al. Cyclic Vomiting Syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med 2005; 3:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/38\">",
"      Li BU, Issenman RM, Sarna SK. Consensus statement--2nd International Scientific Symposium on CVS. The Faculty of The 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. Dig Dis Sci 1999; 44:9S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/39\">",
"      Symon DN, Russell G. Abdominal migraine: a childhood syndrome defined. Cephalalgia 1986; 6:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/40\">",
"      Fitzpatrick E, Bourke B, Drumm B, Rowland M. Outcome for children with cyclical vomiting syndrome. Arch Dis Child 2007; 92:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/41\">",
"      Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/42\">",
"      Schulte-Bockholt A, Kugathasan S, Mesrobian HG, Werlin SL. Ureteropelvic junction obstruction: an overlooked cause of cyclic vomiting. Am J Gastroenterol 2002; 97:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/43\">",
"      Olson AD, Li BU. The diagnostic evaluation of children with cyclic vomiting: a cost-effectiveness assessment. J Pediatr 2002; 141:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/44\">",
"      Vanderhoof JA, Young R, Kaufman SS, Ernst L. Treatment of cyclic vomiting in childhood with erythromycin. J Pediatr Gastroenterol Nutr 1993; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/45\">",
"      Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA. Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine. Pediatrics 1997; 100:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/46\">",
"      Benson JM, Zorn SL, Book LS. Sumatriptan in the treatment of cyclic vomiting. Ann Pharmacother 1995; 29:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/47\">",
"      Pasricha PJ, Schuster MM, Saudek CD, et al. Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac. Am J Gastroenterol 1996; 91:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/48\">",
"      Boyle CA. Management of menstrual migraine. Neurology 1999; 53:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/49\">",
"      Clouse RE, Sayuk GS, Lustman PJ, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. Clin Gastroenterol Hepatol 2007; 5:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34568/abstract/50\">",
"      Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol 2007; 102:2832.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2588 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34568=[""].join("\n");
var outline_f33_48_34568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CVS and migraines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dysautonomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypothalamic-pituitary-adrenal axis defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Food allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Catamenial CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic cannabis use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rome III criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      North American Society for Pediatric Gastroenterology Hepatology and Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Warning signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2588|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?32/6/32867\" title=\"algorithm 1\">",
"      NASPGHN evaluation CVS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2588|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/41/38557\" title=\"figure 1\">",
"      Cyclic versus chronic vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/40/12940\" title=\"table 1\">",
"      Association of CVS migraines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/3/19516\" title=\"table 2\">",
"      Features CVS children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/40/4751\" title=\"table 3\">",
"      Differential diagnosis of cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/7/11388\" title=\"table 4A\">",
"      Lifestyle changes in CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/48/11021\" title=\"table 4B\">",
"      Prophylactic medication CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/9/24733\" title=\"table 4C\">",
"      Supportive abortive Rx CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/36/35403\" title=\"table 4D\">",
"      Rx protocol acute CVS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/46/10988\" title=\"table 5\">",
"      CVS support resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24521?source=related_link\">",
"      Approach to the infant or child with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18490?source=related_link\">",
"      Management of migraine headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8600?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34569="Allergen avoidance in the treatment of asthma and allergic rhinitis";
var content_f33_48_34569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergen avoidance in the treatment of asthma and allergic rhinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Thomas A E Platts-Mills, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34569/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/48/34569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate hypersensitivity to allergens is very common among children and young adults with asthma and rhinitis. Sensitization to one or more of the major indoor allergens (such as dust mite, cat, dog, or cockroach), combined with significant accumulation of relevant allergens in the house, has been consistently found to be the strongest risk factor for asthma in population, case control, and prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. It is possible that certain indoor allergens, such as dust mite, are more important in the pathogenesis of allergic airway disease than others, and this is an area of active investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evidence for a causal relationship between allergen exposure and asthma comes from bronchoprovocation experiments demonstrating that these allergens can induce bronchospasm, eosinophilic airway inflammation, and prolonged increases in bronchial hyperreactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Perhaps more significantly, moving some asthmatic children or adults from their homes to a different, low allergen residential setting results in major improvements in clinical symptoms and bronchial hyperreactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/1,12-14\">",
"     1,12-14",
"    </a>",
"    ]. This background provides a powerful rationale for recommending that allergic patients should reduce allergen exposure in their houses as part of the management of asthma and allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific monoclonal antibody-based assays have been developed to monitor allergen levels during controlled trials and to test the specific measures recommended to control exposure to mite, cat, dog, and cockroach antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. These techniques have facilitated detailed studies of specific allergens and have helped to define effective control measures, although the exquisite specificity of these measurements may mean that some forms of the specific allergen (eg, Der p 1) may escape detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen avoidance is appropriate for symptomatic patients with allergic responses documented either with positive skin tests or serum assays for specific IgE antibodies. Once specific sensitivities have been defined, it is important to implement a comprehensive environmental control plan for all, or as many as possible, of the allergens that are relevant to that patient. Studies in which environmental control has been most effective are those in which the specific measures taken were tailored to the patient and addressed the major allergens to which each patient was sensitized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urban children with moderate-to-severe asthma represent a population that has been studied with regard to the impact of environmental allergen control on asthma. Comprehensive environmental modification in these children has been shown to be effective in reducing asthma symptoms and appears to be cost effective if carefully performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Patient/parent",
"    </span>",
"    education is essential for successful environmental modification. Simply handing a sheet of recommendations to a patient, without providing detailed education about the proposed measures or specific follow-up, is unlikely to be effective. In addition, the clinician should be mindful that major environmental modifications, such as removing carpeting, modifying heating systems, or replacing old upholstered furniture, are expensive and may not be affordable for some families. Recognition of this and an initial emphasis on low-cost interventions should enhance patient cooperation.",
"   </p>",
"   <p>",
"    This topic reviews measures for reducing exposure to indoor allergens. Approaches for minimizing exposure to non-allergic triggers and reducing a patient's sensitivity to allergens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DUST MITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dust mites (Dermatophagoides pteronyssinus and D. farinae) are arachnids that colonize bedding, sofas, carpets, or any woven material. Dust mites do not bite, and aside from causing allergic disease, are not known to pose other harm to humans. It is sometimes difficult to educate patients regarding dust mites because neither the mites, nor their debris, can be seen under normal circumstances.",
"   </p>",
"   <p>",
"    Mites absorb humidity from the atmosphere (ie, they do not drink) and feed on organic matter (including shed human and animal skin particles), usually with the aid of fungal degradation. They require nests to live in, a source of food (rarely a limiting factor when these organisms live indoors), and sufficient humidity. Dust mite infestation is far less common in arid and high-altitude climates, such as the mountain states and southwestern United States.",
"   </p>",
"   <p>",
"    Mite fecal particles contain a complex mixture of allergenic mite-derived proteins, endotoxin, enzymes, and mite and bacterial DNA, all of which can be immunostimulatory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These particles are relatively large and heavy and become transiently airborne after vigorous disturbance, but then settle rapidly, such that no allergen is detectable in the air within 15 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, air filtration plays very little role in controlling exposure to dust mite. Instead, exposure is believed to occur primarily by close proximity to dust mite debris during time spent in bed, on the floor, or on upholstered furniture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective avoidance measures include physical barriers, controlling humidity, and reducing areas that can harbor dust mite colonies. Other measures to reduce exposure to dust mite allergens include heat treatment, insecticides, and allergen-denaturing agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physical barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical barriers used to control domestic allergen exposure include covers for pillows, mattresses, box springs, comforters, and furniture cushions (",
"    <a class=\"graphic graphic_table graphicRef60923 \" href=\"mobipreview.htm?42/20/43339\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The simplest types of covers are plastic, which may be uncomfortable for some patients. Considerable effort has gone into identifying alternative fabrics, including coated plastics, permeable synthetics that allow vapor and air movement, nonwoven synthetics that allow airflow without passage of particles &gt;1 micron in diameter, and finely woven fabrics with pore sizes as small as 2 microns (",
"    <a class=\"graphic graphic_table graphicRef65782 \" href=\"mobipreview.htm?17/57/18332\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/26\">",
"     26",
"    </a>",
"    ]. Woven fabrics with a designated pore size up to approximately 6 microns are preferable, because these are very effective at controlling the passage of mite as well as cat allergens, while still permitting adequate airflow. These fabrics will also completely block the passage of immature and adult live mites. Woven fabrics are identifiable by their smooth texture, higher relative cost, and ability to be laundered repeatedly. In contrast, nonwoven materials, which look and feel similar to heavy weight paper toweling, can retain high levels of allergen on the surface and lose integrity with repeated washing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to counsel patients that the use of bedding covers, as an isolated intervention, is unlikely to reduce rhinitis or asthma symptoms to a clinically meaningful degree. Instead, bedding covers should be a component of a comprehensive plan to reduce exposure to dust mite, as well as any other allergens that are important to that patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large, well-designed trial, over 1100 adults with asthma and dust mite sensitivity were randomly assigned to receive allergen-impermeable bed covers or placebo bed covers that allowed passage of dust mite allergen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/28\">",
"       28",
"      </a>",
"      ]. Allergen impermeable covers were associated with significant decreases in dust mite allergen in mattress dust, although asthma symptoms were not significantly reduced.",
"     </li>",
"     <li>",
"      In a systematic review that included just two trials, the reviewers concluded controlled trials of allergen avoidance for perennial allergic rhinitis were not convincing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/29\">",
"       29",
"      </a>",
"      ]. This was partly for technical reasons in assessing symptoms but also because only a limited number of patients were selectively allergic to dust mite.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even though the use of dust-mite impermeable bedding covers, as an",
"    <strong>",
"     isolated",
"    </strong>",
"    intervention, is probably not sufficient to produce clinical improvement in most patients, this intervention is nevertheless considered an essential component of any strategy to reduce dust mite exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. The more generalizable point is that effective allergen avoidance must target all of the allergens that are important for that patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/28,31,32\">",
"     28,31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Impact on asthma control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Minimizing upholstery and fabric reservoirs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts should be made to restrict the presence of carpets, upholstered furniture, and drapes in the environment of the dust-mite allergic person, in order to reduce the sites that can be colonized by dust mites. Dusting of surfaces and vacuuming of floors, using a vacuum equipped with a high-efficiency particular air (HEPA) filter, should be performed regularly. The numbers of stuffed toys in children's bedrooms should be minimized. Carpeting can be removed and replaced with finished floors and washable area rugs.",
"   </p>",
"   <p>",
"    These measures are particularly important in the rooms where the patient spends the greatest amount of time, such as the bedroom, study, and rooms where the television and computer are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Regulation of humidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreasing humidity can reduce mite growth, and maintaining relative humidity below 50 percent is recommended. This can be accomplished by the regular opening of windows in a dry climate or air conditioning in a humid climate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/33\">",
"     33",
"    </a>",
"    ]. Humidifier use should be avoided. Dehumidifiers can be used, although these do not generally filter the air as air conditioners do. Patients who report dry nasal passages should use saline nasal sprays before bed instead of humidifying the entire bedroom.",
"   </p>",
"   <p>",
"    Upper floors usually have less humidity than lower floors because carpets laid on concrete slabs in a basement or at ground level tend to become and remain damp, after which they can become a rich source of bacterial, fungal, and dust mite allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/34\">",
"     34",
"    </a>",
"    ]. In some climates (eg, Boston, Massachusetts), apartments have dramatically less humidity than houses and commonly have up to 10-fold less mite allergen. In such situations, moving to an apartment on the second floor or higher may be an effective method of reducing dust mite exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Heat treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both dry heat and steam treatments can eradicate dust mites and reduce exposure to mite allergens. One study demonstrated that commercial steam cleaning of carpets kills dust mites and reduces dust mite allergen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, asthmatic patients were randomized to receive treatment of mattresses and duvets with hot air (110&deg; C) and steam, as well as steam cleaning of carpets versus sham treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/36\">",
"     36",
"    </a>",
"    ]. A single active environmental treatment resulted in a significant and sustained reduction in Der p 1 and 2 dust mite allergen concentrations, and a reduction in bronchial reactivity as determined by bronchoprovocation testing that was maintained for 9 to 12 months.",
"   </p>",
"   <p>",
"    Washing sheets, pillowcases, mattress pads, and blankets weekly effectively reduces mite counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/37\">",
"     37",
"    </a>",
"    ]. We recommend that bedding be washed in hot water with detergent, or dried in an electric clothes dryer on a hot setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Insecticides and allergen-denaturing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of chemicals to kill mites or denature allergens has also been investigated, but the data in favor of this approach are modest. Several chemicals have been tested, but only benzyl benzoate and tannic acid have been marketed in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzyl benzoate is highly toxic to mites in the laboratory setting, but when applied to carpets, produces only a modest decrease in allergens (&lt;60 percent) that is short-lived [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tannic acid potently denatures proteins in vitro, but has a minimal effect when applied to carpets that harbor mites and other allergens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged eradication of mites is not possible with currently available chemicals. Newer formulations of benzyl benzoate may be more effective, although these would require further evaluation before their routine use could be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Impact on asthma control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small controlled trials have successfully documented a decrease in mite allergen for six months or more following a range of interventions (",
"    <a class=\"graphic graphic_table graphicRef66390 \" href=\"mobipreview.htm?25/2/25644\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/1,28,36,41-44\">",
"     1,28,36,41-44",
"    </a>",
"    ]. Each of these studies reported benefit, and four studies found a highly significant decrease in nonspecific bronchial hyperreactivity. It is important to note that over half of the reported trials of dust mite avoidance have failed because the measures proposed did not reduce allergen exposure for a significant period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several conclusions from these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful controlled trials have used combinations of physical measures, including pillow covers, mattress covers, washing bedding in hot water, and carpet removal, rather than chemical treatments.",
"     </li>",
"     <li>",
"      At least three to six months of sustained intervention was necessary to demonstrate clinical benefit. Thus, patients should be encouraged to adopt dust mite control measures that they can effectively sustain over time, and they should be advised that symptoms are expected to improve gradually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoor pets are a common source of allergens, and the vast majority of pet-allergic patients are reactive to cats, dogs, or both. However, a growing number of exotic animals are kept as pets, including reptiles, birds, insects, rodents, ferrets, and monkeys, and allergic responses to these animals are also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most effective measure in controlling allergens derived from animals is to persuade the family or patient not to keep animals in the house. Scales shed from the animal's skin (comparable to human dander) are the major source of animal allergens. Keeping a pet outdoors is effective, but restricting the animal to one part of the house is ineffective because animal allergens, particularly those from cats, are easily carried on clothing. Both cat and dog allergens can remain airborne for extended periods of time due to carriage on particles that, because of their small size, settle very slowly.",
"   </p>",
"   <p>",
"    Because so many patients refuse to give away their animals, efforts have been made to control cat allergen while the animal remains in the house (",
"    <a class=\"graphic graphic_table graphicRef81363 \" href=\"mobipreview.htm?15/21/15707\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/47\">",
"     47",
"    </a>",
"    ]. The clinical effectiveness of these measures is not well established, and patients must understand that the presence of a cat in the house represents such a large source of allergen that none of the proposed measures can consistently control allergen exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even when cats are removed from the house, allergens persist for many weeks or months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/49\">",
"     49",
"    </a>",
"    ]. This phenomenon explains the increase in symptoms sometimes observed when a cat-allergic patient moves into a home in which cats were previously living. Aggressive cleaning measures can accelerate the removal of allergens, but the quantity of cat allergen that accumulates in carpets, sofas, and mattresses represents a major reservoir that is difficult to remove with routine cleaning.",
"   </p>",
"   <p>",
"    Cat allergen is transferred on clothing and can easily be detected in schools and in houses without a cat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The quantities found in these sites are sometimes surprisingly high, such as 80 mcg per gram of dust of the antigen Fel d 1 (the major cat allergen) or Can f 1 (the major dog allergen). In some cases, this is well within the range of allergen concentration found in homes with an animal. Furthermore, this passively transferred allergen can become airborne and cause symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Patients who are highly allergic to cat or dog allergens should be informed about this potential source of ongoing exposure so that they can better understand their symptom patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Specific measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In homes without a pet, levels of animal allergen may be effectively reduced through aggressive cleaning and the use of room air cleaners (",
"    <a class=\"graphic graphic_table graphicRef81363 \" href=\"mobipreview.htm?15/21/15707\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/1,47\">",
"     1,47",
"    </a>",
"    ]. As mentioned previously, patients should be counseled that these measures are unlikely to be effective if the animal remains in the home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Air filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, room air cleaners will only be effective if allergen reservoirs (including the pet itself as well as old carpets and upholstered furniture) are removed, because otherwise the air currents they create can increase the quantity of allergen becoming airborne. Air cleaners can reduce the concentration of airborne animal allergens, although studies have reported conflicting results regarding the impact of this reduction on symptoms of allergic rhinitis and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/48,55\">",
"     48,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An expert panel, organized by the American Academy of Allergy, Asthma, and Immunology, conducted a systematic review concluding that there was evidence of benefit from the use of air filters in patients with allergic airway disease, but neither the magnitude of the effect nor the optimal techniques had been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/56\">",
"     56",
"    </a>",
"    ]. In most positive studies, clinical benefit was demonstrated only after a prolonged period of use (eg, a minimum of one year). Based on the available studies, that panel suggested that allergic patients choose one of the following options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A room air cleaner with a HEPA filter, particularly one that directs filtered air toward the individual's head during sleep",
"     </li>",
"     <li>",
"      A whole house filtration system for homes with forced air heating, with disposable HEPA filters that are regularly changed (a relatively expensive option)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Aggressive cleaning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular cleaning and the use of a vacuum cleaner with an effective filtration system are recommended. A controlled trial has reported lower allergen levels and clinical improvement in asthma measures in homes cleaned with vacuums equipped with high-efficiency particulate air (HEPA) filters, compared to vacuums without specialized filters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/57\">",
"     57",
"    </a>",
"    ]. The homes in that study did not have pets, but the treatment was effective for cat allergic subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bathing pets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of bathing pets regularly has been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/47,58,59\">",
"     47,58,59",
"    </a>",
"    ]. Washing cats less often than weekly is unlikely to result in any meaningful improvement in symptoms, as some studies have shown that cat allergen in the air returns to pre-bath levels as quickly as 24 hours later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/59\">",
"     59",
"    </a>",
"    ]. The effect of washing dogs regularly has been less well studied; twice weekly bathing may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     \"Hypoallergenic\" breeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of this review, there is no published scientific literature confirming the existence of &ldquo;hypoallergenic&rdquo; breeds of cats or dogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620079\">",
"    <span class=\"h4\">",
"     Cats",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of people with cat allergy are sensitized to the Fel d1 protein. A \"hypoallergenic cat\" has been commercially developed (Allerca; San Diego, California) by breeding cats that were naturally deficient in Fel d1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/60\">",
"     60",
"    </a>",
"    ]. The cost of these animals is significant (between $6500 and $23,000per cat). Preliminary studies exposing cat-allergic subjects to the animals showed few symptoms, although no allergen measurements have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/61\">",
"     61",
"    </a>",
"    ]. Further information is required to understand the clinical responses of cat-allergic individuals to these animals, both with short-term and prolonged exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620086\">",
"    <span class=\"h4\">",
"     Dogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no convincing evidence that certain breeds of dogs are less allergenic than others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/62\">",
"     62",
"    </a>",
"    ]. The best study to date compared concentrations of the major dog allergen Can f1 in samples from two groups of dogs and the homes they occupied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/63\">",
"     63",
"    </a>",
"    ]. The first group of 196 dogs consisted of breeds that are promoted on the internet or by breeders as &ldquo;hypoallergenic&rdquo; (eg, Labradoodle, Poodle, Spanish Waterdog, Airedale terrier) and the second, 160 dogs of breeds that carry no such claims (Labrador retriever and 46 other breeds, as well as various mixed breeds). Can f1 concentrations in the animals&rsquo; coats, and in the settled and airborne dusts from their homes were compared. No differences were found in allergen levels in the homes of the two groups. Interestingly, concentrations of allergen in hair samples from the hypoallergenic group were significantly higher than those of the control group, although this was not reflected in home dust levels. Within each breed, there was marked variability among individual animals, a phenomenon also noted in earlier studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. This study confirmed the findings of an earlier, smaller study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allerca",
"    <sup>",
"    </sup>",
"    also markets a hypoallergenic dog [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/60\">",
"     60",
"    </a>",
"    ]. As with the Allerca cats, data documenting that these animals produce lower levels of allergens have not been made available to the general scientific community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RODENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice and rats produce urinary proteins that are allergenic in occupational (eg, laboratory workers), school [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], and domestic settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. Mouse allergens are measurable in nearly all inner-city, multifamily homes, and as many as 50 percent of suburban homes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, the levels in inner-city homes have been as much as 100-fold higher than those in suburban homes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/74\">",
"     74",
"    </a>",
"    ], and levels in inner city schools are often higher than in homes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure of infants to mice allergens has been associated with the development of asthma, independent of other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/75\">",
"     75",
"    </a>",
"    ]. Mouse exposure also correlates with poorer asthma control and increased health care utilization in inner-city children sensitized to mouse allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/76\">",
"     76",
"    </a>",
"    ]. In adults in the community (non-laboratory workers), sensitization to mouse allergens is significantly associated with asthma and asthma morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to rodents can be assessed by asking if mice or rats are ever sighted at home or if the family has seen evidence of their presence (droppings, nests). However, mouse allergen can be high even if the answers to these questions are negative, as rodents may remain entirely hidden from sight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Specific control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional extermination and integrated pest management are usually necessary to reduce rodent allergen levels significantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition to extermination, keeping food and trash in covered containers, cleaning food scraps from the floor and countertops, and sealing cracks in the walls, doors, and floors are essential for ongoing control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COCKROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence that allergens derived from the German cockroach, Blattella germanica, are important in the cities of North America has come from case control studies and provocation studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/51,80,81\">",
"     51,80,81",
"    </a>",
"    ]. As an example, one study of 476 children found that the combination of specific skin test positivity and exposure to cockroach allergen was associated with significantly higher rates of hospitalization, compared to when this combination was absent (0.37 versus 0.11 hospitalizations per child per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Specific control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current recommendations include placing multiple baited traps or poisons, eliminating potential food sources (such as refuse and unwashed dishes), and removing reservoirs of cockroach debris and standing water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/78\">",
"     78",
"    </a>",
"    ]. Air filtration is not helpful in reducing cockroach allergen exposure, as the allergen settles quickly and does not remain airborne.",
"   </p>",
"   <p>",
"    Despite the ability to measure cockroach allergen and a good understanding of the measures necessary to reduce exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/84\">",
"     84",
"    </a>",
"    ], initial interventional trials were generally unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. It is likely that cockroach allergen reduction alone is not sufficient to impact symptoms, as was demonstrated in other studies targeting single allergens. This may be particularly true for patients living in poor conditions, who may be exposed to high levels of multiple allergens. However, a subsequent trial that included a combined strategy to reduce exposure to cockroach, mite, and other indoor asthma triggers was successful in reducing symptoms and improving lung function in urban children with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ASIAN LADYBUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asian ladybugs (ALB) (Harmonia axyridis) were imported to the United States from 1916 until 1990 as a biological means of controlling aphids. It was anticipated that the insects would not survive the cold of winter; however, they adapted by swarming and invading houses when temperatures drop in the early fall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. Allergy to Asian ladybugs has been increasingly reported as a source of seasonal indoor respiratory symptoms, particularly chronic cough, rhinitis, and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/89\">",
"     89",
"    </a>",
"    ]. Most cases have been reported in rural areas of the central, mid-western, and southern United States. They can also bite and cause local reactions.",
"   </p>",
"   <p>",
"    Asian ladybugs enter homes through external cracks and crevices, and then infest spaces within walls. They secrete a brown liquid that may stain walls and produce an unpleasant smell when handled. The source of the allergen(s) is not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extracts for allergy skin testing and ALB-specific IgE immunoassays are not yet commercially available. Some allergy specialists in affected communities have produced extracts for skin testing using the beetles directly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Specific control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary protection is to have tight windows and walls to decrease access of these insects. The next most promising control measure identified to date is treatment of the outside of a house with pyrethroid chemicals prior to cold weather [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/89,91\">",
"     89,91",
"    </a>",
"    ]. Other measures, such as treating the already-infested walls with chemicals, sound waves, and traps have not been consistently helpful. In cases of severe allergy, it may be necessary for patients to move to a more tightly-built house or into a more urban area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INDOOR MOLDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoor molds and fungi are most problematic in homes with high humidity, standing water, or water damage. If the home of a mold-allergic patient contains visible mold or smells of mold, then remediation for this allergen is in order.",
"   </p>",
"   <p>",
"    A randomized trial of indoor mold remediation in patients with asthma and visible mold growth in the home demonstrated benefit, regardless of whether patients were sensitized to four common allergenic molds by skin prick testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/92\">",
"     92",
"    </a>",
"    ]. In this study, which did not include a",
"    <span class=\"nowrap\">",
"     placebo/sham",
"    </span>",
"    intervention, 164 homes housing 232 asthmatic patients were randomly assigned to undergo cleaning with detergent and fungicide and installation of an attic fan, or to have this intervention performed one year later. Some subjects in the control group performed mold remediation on their own. Despite this, there was a dramatic difference between the two groups at six months, with improvement in breathing symptoms in 52 and 0 percent of patients in the intervention and control groups, respectively, although some placebo effect was possible. Medication use decreased 41 percent in the intervention group, and increased 17 percent among control patients. The benefit in patients not sensitized to the four tested molds was posited to be secondary to reduction in mycotoxins and volatile irritant substances emitted by molds. However, the effect could also reflect a failure to identify allergic patients when using only four molds and prick tests. Another similar randomized trial also found modest benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34569/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Specific measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent and remediate indoor mold contamination are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11110?source=see_link&amp;anchor=H18#H18\">",
"     \"Assessment of mold in the indoor environment\", section on 'Prevention and remediation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OUTDOOR ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outdoor allergens, especially pollens and molds, are difficult to avoid short of limiting contact with the outside world. Patients with pollen and mold allergies should be advised to close the windows at home and also in the car, stay indoors when possible, and use air conditioners to filter the air during times of peak symptoms. Showering before bed to remove allergens from hair and skin can help reduce contamination of the bedding. Over the counter saline sprays and rinses can be used to wash allergens from the nasal lining after outdoor exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=see_link\">",
"       \"Patient information: Avoiding asthma triggers (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=see_link\">",
"       \"Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective indoor allergen avoidance begins with identification of those allergens that are relevant to a specific patient, either through a careful history, or preferably, with specific allergy testing. Once the patient's sensitivities have been defined, specific measures for each allergen should be implemented.",
"     </li>",
"     <li>",
"      The principals of environmental allergen control are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Control potential sources of allergen (eg, pets, rodents, cockroaches)",
"     </li>",
"     <li>",
"      Minimize sites in which mold or mites can grow",
"     </li>",
"     <li>",
"      Minimize reservoirs of allergen (eg, upholstered sofas, carpets, and uncovered pillows or bedding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic measures for the major indoor allergens are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef58870 \" href=\"mobipreview.htm?35/14/36076\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Reducing indoor exposure to dust mites, animal dander, or cockroach debris, is relatively straightforward, although it can be costly. Clinicians should recognize this and emphasize less expensive measures initially.",
"     </li>",
"     <li>",
"      Problems arise when severely allergic patients will not give up pets, or are unwilling or unable to remove carpets, control supplies of potential food for cockroaches, and adequately reduce humidity. Results are less likely to be successful if the patient is being exposed outside the home (eg, cat or cockroach allergens at school).",
"     </li>",
"     <li>",
"      For motivated patients who have adequate resources, we suggest the implementation of avoidance measures for all of the indoor allergens to which the patient is sensitized (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/1\">",
"      Platts-Mills TA, Vervloet D, Thomas WR, et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/2\">",
"      Peat JK, Tovey E, Toelle BG, et al. House dust mite allergens. A major risk factor for childhood asthma in Australia. Am J Respir Crit Care Med 1996; 153:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/3\">",
"      Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/4\">",
"      Sears MR, Herbison GP, Holdaway MD, et al. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989; 19:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/5\">",
"      Squillace SP, Sporik RB, Rakes G, et al. Sensitization to dust mites as a dominant risk factor for asthma among adolescents living in central Virginia. Multiple regression analysis of a population-based study. Am J Respir Crit Care Med 1997; 156:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/6\">",
"      Erwin EA, Custis NJ, Satinover SM, et al. Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase. J Allergy Clin Immunol 2005; 115:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/7\">",
"      Erwin EA, R&ouml;nmark E, Wickens K, et al. Contribution of dust mite and cat specific IgE to total IgE: relevance to asthma prevalence. J Allergy Clin Immunol 2007; 119:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/8\">",
"      Erwin EA, Wickens K, Custis NJ, et al. Cat and dust mite sensitivity and tolerance in relation to wheezing among children raised with high exposure to both allergens. J Allergy Clin Immunol 2005; 115:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/9\">",
"      Platts-Mills TA. The role of indoor allergens in chronic allergic disease. J Allergy Clin Immunol 2007; 119:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/10\">",
"      Cockcroft DW, Ruffin RE, Frith PA, et al. Determinants of allergen-induced asthma: dose of allergen, circulating IgE antibody concentration, and bronchial responsiveness to inhaled histamine. Am Rev Respir Dis 1979; 120:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/11\">",
"      Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994; 94:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/12\">",
"      Platts-Mills TA, Tovey ER, Mitchell EB, et al. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     Kerrebijn KF. Endogenous factors in childhood CNSLD: Methodological aspects in population studies. In: Bronchitis III, Orie NGM, van der Lende R (Eds), Royal Vangorcum Assen, The Netherlands 1970. p.38.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/14\">",
"      Piacentini GL, Martinati L, Mingoni S, Boner AL. Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. J Allergy Clin Immunol 1996; 97:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/15\">",
"      Sharma HP, Hansel NN, Matsui E, et al. Indoor environmental influences on children's asthma. Pediatr Clin North Am 2007; 54:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/16\">",
"      Erwin EA, Platts-Mills TA. Allergens. Immunol Allergy Clin North Am 2005; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/17\">",
"      Luczynska CM, Arruda LK, Platts-Mills TA, et al. A two-site monoclonal antibody ELISA for the quantification of the major Dermatophagoides spp. allergens, Der p I and Der f I. J Immunol Methods 1989; 118:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/18\">",
"      Chapman MD, Aalberse RC, Brown MJ, Platts-Mills TA. Monoclonal antibodies to the major feline allergen Fel d I. II. Single step affinity purification of Fel d I, N-terminal sequence analysis, and development of a sensitive two-site immunoassay to assess Fel d I exposure. J Immunol 1988; 140:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/19\">",
"      van Ree R. Indoor allergens: relevance of major allergen measurements and standardization. J Allergy Clin Immunol 2007; 119:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/20\">",
"      Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/21\">",
"      van Schayck OC, Maas T, Kaper J, et al. Is there any role for allergen avoidance in the primary prevention of childhood asthma? J Allergy Clin Immunol 2007; 119:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/22\">",
"      Kattan M, Stearns SC, Crain EF, et al. Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma. J Allergy Clin Immunol 2005; 116:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/23\">",
"      Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999; 104:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/24\">",
"      Ghaemmaghami AM, Robins A, Gough L, et al. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL-4 and less IFN-gamma. Eur J Immunol 2001; 31:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/25\">",
"      Tovey ER, Chapman MD, Wells CW, Platts-Mills TA. The distribution of dust mite allergen in the houses of patients with asthma. Am Rev Respir Dis 1981; 124:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/26\">",
"      Vaughan JW, McLaughlin TE, Perzanowski MS, Platts-Mills TA. Evaluation of materials used for bedding encasement: effect of pore size in blocking cat and dust mite allergen. J Allergy Clin Immunol 1999; 103:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/27\">",
"      Miller JD, Naccara L, Satinover S, Platts-Mills TA. Nonwoven in contrast to woven mattress encasings accumulate mite and cat allergen. J Allergy Clin Immunol 2007; 120:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/28\">",
"      Woodcock A, Forster L, Matthews E, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/29\">",
"      Nurmatov U, van Schayck CP, Hurwitz B, Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy 2012; 67:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/30\">",
"      Shedd AD, Peters JI, Wood P, et al. Impact of home environment characteristics on asthma quality of life and symptom scores. J Asthma 2007; 44:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/31\">",
"      Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003; 349:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/32\">",
"      Luczynska C, Tredwell E, Smeeton N, Burney P. A randomized controlled trial of mite allergen-impermeable bed covers in adult mite-sensitized asthmatics. Clin Exp Allergy 2003; 33:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/33\">",
"      Korsgaard J. House-dust mites and absolute indoor humidity. Allergy 1983; 38:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/34\">",
"      Platts-Mills TA, Hayden ML, Chapman MD, Wilkins SR. Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. J Allergy Clin Immunol 1987; 79:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/35\">",
"      Colloff MJ, Taylor C, Merrett TG. The use of domestic steam cleaning for the control of house dust mites. Clin Exp Allergy 1995; 25:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/36\">",
"      Htut T, Higenbottam TW, Gill GW, et al. Eradication of house dust mite from homes of atopic asthmatic subjects: a double-blind trial. J Allergy Clin Immunol 2001; 107:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/37\">",
"      McDonald LG, Tovey E. The role of water temperature and laundry procedures in reducing house dust mite populations and allergen content of bedding. J Allergy Clin Immunol 1992; 90:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/38\">",
"      Miller JD, Miller A. Ten minutes in a clothes dryer kills all mites in blankets. J Allergy Clin Immunol 1996; 97:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/39\">",
"      Hayden ML, Rose G, Diduch KB, et al. Benzyl benzoate moist powder: investigation of acaricidal [correction of acarical] activity in cultures and reduction of dust mite allergens in carpets. J Allergy Clin Immunol 1992; 89:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/40\">",
"      Woodfolk JA, Hayden ML, Miller JD, et al. Chemical treatment of carpets to reduce allergen: a detailed study of the effects of tannic acid on indoor allergens. J Allergy Clin Immunol 1994; 94:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/41\">",
"      Murray AB, Ferguson AC. Dust-free bedrooms in the treatment of asthmatic children with house dust or house dust mite allergy: a controlled trial. Pediatrics 1983; 71:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/42\">",
"      Ehnert B, Lau-Schadendorf S, Weber A, et al. Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 1992; 90:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/43\">",
"      Walshaw MJ, Evans CC. Allergen avoidance in house dust mite sensitive adult asthma. Q J Med 1986; 58:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/44\">",
"      G&oslash;tzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. BMJ 1998; 317:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/45\">",
"      Platts-Mills TA, Chapman MD, Wheatly LM. Control of house dust mite in managing asthma. Conclusions of meta-analysis are wrong. BMJ 1999; 318:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/46\">",
"      Phillips JF, Lockey RF. Exotic pet allergy. J Allergy Clin Immunol 2009; 123:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/47\">",
"      de Blay F, Chapman MD, Platts-Mills TA. Airborne cat allergen (Fel d I). Environmental control with the cat in situ. Am Rev Respir Dis 1991; 143:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/48\">",
"      Wood RA, Johnson EF, Van Natta ML, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med 1998; 158:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/49\">",
"      Wood RA, Chapman MD, Adkinson NF Jr, Eggleston PA. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol 1989; 83:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/50\">",
"      Custovic A, Green R, Taggart SC, et al. Domestic allergens in public places. II: Dog (Can f1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings. Clin Exp Allergy 1996; 26:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/51\">",
"      Gelber LE, Seltzer LH, Bouzoukis JK, et al. Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. Am Rev Respir Dis 1993; 147:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/52\">",
"      Perzanowski MS, R&ouml;nmark E, Nold B, et al. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. J Allergy Clin Immunol 1999; 103:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/53\">",
"      Almqvist C, Wickman M, Perfetti L, et al. Worsening of asthma in children allergic to cats, after indirect exposure to cat at school. Am J Respir Crit Care Med 2001; 163:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/54\">",
"      Bollinger ME, Eggleston PA, Flanagan E, Wood RA. Cat antigen in homes with and without cats may induce allergic symptoms. J Allergy Clin Immunol 1996; 97:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/55\">",
"      van der Heide S, van Aalderen WM, Kauffman HF, et al. Clinical effects of air cleaners in homes of asthmatic children sensitized to pet allergens. J Allergy Clin Immunol 1999; 104:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/56\">",
"      Sublett JL, Seltzer J, Burkhead R, et al. Air filters and air cleaners: rostrum by the American Academy of Allergy, Asthma &amp; Immunology Indoor Allergen Committee. J Allergy Clin Immunol 2010; 125:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/57\">",
"      Popplewell EJ, Innes VA, Lloyd-Hughes S, et al. The effect of high-efficiency and standard vacuum-cleaners on mite, cat and dog allergen levels and clinical progress. Pediatr Allergy Immunol 2000; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/58\">",
"      Avner DB, Perzanowski MS, Platts-Mills TA, Woodfolk JA. Evaluation of different techniques for washing cats: quantitation of allergen removed from the cat and the effect on airborne Fel d 1. J Allergy Clin Immunol 1997; 100:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/59\">",
"      Nageotte C, Park M, Havstad S, et al. Duration of airborne Fel d 1 reduction after cat washing. J Allergy Clin Immunol 2006; 118:521.",
"     </a>",
"    </li>",
"    <li>",
"     The company's website is available at the following address: file://www.allerca.com/html/hypoallergenic.html (Accessed on August 10, 2012).",
"    </li>",
"    <li>",
"     Spector S, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/62\">",
"      Lockey RF. The myth of hypoallergenic dogs (and cats). J Allergy Clin Immunol 2012; 130:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/63\">",
"      Vredegoor DW, Willemse T, Chapman MD, et al. Can f 1 levels in hair and homes of different dog breeds: lack of evidence to describe any dog breed as hypoallergenic. J Allergy Clin Immunol 2012; 130:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/64\">",
"      Ramadour M, Guetat M, Guetat J, et al. Dog factor differences in Can f 1 allergen production. Allergy 2005; 60:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/65\">",
"      Heutelbeck AR, Schulz T, Bergmann KC, Hallier E. Environmental exposure to allergens of different dog breeds and relevance in allergological diagnostics. J Toxicol Environ Health A 2008; 71:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/66\">",
"      Nicholas CE, Wegienka GR, Havstad SL, et al. Dog allergen levels in homes with hypoallergenic compared with nonhypoallergenic dogs. Am J Rhinol Allergy 2011; 25:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/67\">",
"      Sheehan WJ, Rangsithienchai PA, Muilenberg ML, et al. Mouse allergens in urban elementary schools and homes of children with asthma. Ann Allergy Asthma Immunol 2009; 102:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/68\">",
"      Permaul P, Hoffman E, Fu C, et al. Allergens in urban schools and homes of children with asthma. Pediatr Allergy Immunol 2012; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/69\">",
"      Platts-Mills TA, Longbottom J, Edwards J, et al. Occupational asthma and rhinitis related to laboratory rats: serum IgG and IgE antibodies to the rat urinary allergen. J Allergy Clin Immunol 1987; 79:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/70\">",
"      Eggleston PA, Ansari AA, Ziemann B, et al. Occupational challenge studies with laboratory workers allergic to rats. J Allergy Clin Immunol 1990; 86:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/71\">",
"      Phipatanakul W, Eggleston PA, Wright EC, et al. Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma. J Allergy Clin Immunol 2000; 106:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/72\">",
"      Matsui EC, Simons E, Rand C, et al. Airborne mouse allergen in the homes of inner-city children with asthma. J Allergy Clin Immunol 2005; 115:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/73\">",
"      Chew GL, Perzanowski MS, Miller RL, et al. Distribution and determinants of mouse allergen exposure in low-income New York City apartments. Environ Health Perspect 2003; 111:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/74\">",
"      Matsui EC, Wood RA. Questions physicians often ask about allergens that trigger asthma. J Respir Dis 2006; 27:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/75\">",
"      Phipatanakul W, Celed&oacute;n JC, Sredl DL, et al. Mouse exposure and wheeze in the first year of life. Ann Allergy Asthma Immunol 2005; 94:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/76\">",
"      Matsui EC, Eggleston PA, Buckley TJ, et al. Household mouse allergen exposure and asthma morbidity in inner-city preschool children. Ann Allergy Asthma Immunol 2006; 97:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/77\">",
"      Phipatanakul W, Litonjua AA, Platts-Mills TA, et al. Sensitization to mouse allergen and asthma and asthma morbidity among women in Boston. J Allergy Clin Immunol 2007; 120:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/78\">",
"      Sheehan WJ, Rangsithienchai PA, Wood RA, et al. Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma &amp; Immunology Indoor Allergy/Air Pollution Committee. J Allergy Clin Immunol 2010; 125:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/79\">",
"      Phipatanakul W, Cronin B, Wood RA, et al. Effect of environmental intervention on mouse allergen levels in homes of inner-city Boston children with asthma. Ann Allergy Asthma Immunol 2004; 92:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/80\">",
"      Call RS, Smith TF, Morris E, et al. Risk factors for asthma in inner city children. J Pediatr 1992; 121:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/81\">",
"      Kang B, Vellody D, Homburger H, Yunginger JW. Cockroach cause of allergic asthma. Its specificity and immunologic profile. J Allergy Clin Immunol 1979; 63:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/82\">",
"      Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/83\">",
"      Wang J, Visness CM, Calatroni A, et al. Effect of environmental allergen sensitization on asthma morbidity in inner-city asthmatic children. Clin Exp Allergy 2009; 39:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/84\">",
"      Sever ML, Arbes SJ Jr, Gore JC, et al. Cockroach allergen reduction by cockroach control alone in low-income urban homes: a randomized control trial. J Allergy Clin Immunol 2007; 120:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/85\">",
"      Gergen PJ, Mortimer KM, Eggleston PA, et al. Results of the National Cooperative Inner-City Asthma Study (NCICAS) environmental intervention to reduce cockroach allergen exposure in inner-city homes. J Allergy Clin Immunol 1999; 103:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/86\">",
"      Carter MC, Perzanowski MS, Raymond A, Platts-Mills TA. Home intervention in the treatment of asthma among inner-city children. J Allergy Clin Immunol 2001; 108:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/87\">",
"      Yarbrough JA, Armstrong JL, Blumberg MZ, et al. Allergic rhinoconjunctivitis caused by Harmonia axyridis (Asian lady beetle, Japanese lady beetle, or lady bug). J Allergy Clin Immunol 1999; 104:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/88\">",
"      Sharma K, Muldoon SB, Potter MF, Pence HL. Ladybug hypersensitivity among residents of homes infested with ladybugs in Kentucky. Ann Allergy Asthma Immunol 2006; 97:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/89\">",
"      Nakazawa T, Satinover SM, Naccara L, et al. Asian ladybugs (Harmonia axyridis): a new seasonal indoor allergen. J Allergy Clin Immunol 2007; 119:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/90\">",
"      Goetz DW. Harmonia axyridis ladybug invasion and allergy. Allergy Asthma Proc 2008; 29:123.",
"     </a>",
"    </li>",
"    <li>",
"     Information about ladybug control measures is available through the Internet at: ipm.osu.edu/lady/lady.htm (Accessed on June 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/92\">",
"      Burr ML, Matthews IP, Arthur RA, et al. Effects on patients with asthma of eradicating visible indoor mould: a randomised controlled trial. Thorax 2007; 62:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34569/abstract/93\">",
"      Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect 2006; 114:1574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 530 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34569=[""].join("\n");
var outline_f33_48_34569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DUST MITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physical barriers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Minimizing upholstery and fabric reservoirs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Regulation of humidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Heat treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Insecticides and allergen-denaturing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Impact on asthma control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Specific measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Air filters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Aggressive cleaning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bathing pets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - \"Hypoallergenic\" breeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H620079\">",
"      Cats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H620086\">",
"      Dogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RODENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Specific control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COCKROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Specific control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ASIAN LADYBUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Specific control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INDOOR MOLDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Specific measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OUTDOOR ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/20/43339\" title=\"table 1\">",
"      Dust mites avoidance measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/57/18332\" title=\"table 2\">",
"      Fabrics decrease dust mites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/2/25644\" title=\"table 3\">",
"      Allergen avoidance trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/21/15707\" title=\"table 4\">",
"      Animal dander avoidance steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/14/36076\" title=\"table 5\">",
"      Indoor allergen reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11110?source=related_link\">",
"      Assessment of mold in the indoor environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/2/16419?source=related_link\">",
"      Patient information: Avoiding asthma triggers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=related_link\">",
"      Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34570="HLA and ABO sensitization and desensitization in renal transplantation";
var content_f33_48_34570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HLA and ABO sensitization and desensitization in renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Christina Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/48/34570/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/48/34570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a marked increase in the number of living donor allografts (LDA) performed annually, many potential recipients with otherwise suitable donors are relegated to the ever expanding deceased donor waiting list secondary to either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preformed Human Leukocyte Antigen (HLA) antibodies. These are acquired via pregnancy, transfusion, or prior transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABO blood group incompatibility (ABOI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If not adequately removed, the presence of such antibodies is likely to result in severe antibody mediated rejection (AMR) and early graft loss. Antibody mediated rejection or \"humoral\" rejection was recognized early in the history of transplantation as hyperacute rejection caused by the presence of preformed antibodies (\"humors\") to donor blood group ABO or HLA antigens. Introduction of pretransplant crossmatch techniques and the use of ABO compatible donors essentially eliminated hyperacute rejection.",
"   </p>",
"   <p>",
"    With a wait list time of several years, and a disproportionately longer time for patients with blood group B or O, the time spent on dialysis waiting for the appropriate deceased donor allograft (DDA) to whom such antibodies do not exist in the potential allograft recipient can have a significant adverse effect on both quality and quantity of life. Preemptive transplantation (performed prior to the need for dialysis) provides improved patient and allograft survival as compared to results in patients maintained on dialysis for an extended period of time prior to transplantation.",
"   </p>",
"   <p>",
"    Approximately 16 percent of patients currently on the DDA waiting list are highly presensitized to HLA antigens (defined as &ge;80 percent panel reactive antibody [PRA]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, such patients are less likely to be transplanted or will spend an extended period of time on the waiting list pending availability of a suitable donor kidney. Many of these patients have potential living donors that are excluded without further workup based upon an initial positive crossmatch with the potential recipient, indicating the presence of preformed HLA antibodies. Similarly, based upon the distribution of blood groups in the United States, approximately one-third of potential living donors are eliminated from consideration based on ABOI.",
"   </p>",
"   <p>",
"    Patients with a willing but HLA- or ABO- incompatible donor may wait for a deceased donor organ or receive a living donor organ through desensitization, kidney paired donation or a combination of both. The choice between desensitization or kidney paired donation for an individual recipient depends upon the likelihood of finding a suitable match through kidney paired donation and the chances of successful desensitization.",
"   </p>",
"   <p>",
"    The increased risk of hyperacute antibody mediated rejection (AMR) and subsequent allograft loss when transplanting against either preformed HLA antibodies or ABOI has engendered a general avoidance of this practice. However, reports of successful transplantation across HLA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ABO barriers using various desensitization protocols designed to reduce the amount of preexisting antibody to a level that allows for successful engraftment has stimulated increased interest in using immunologically incompatible grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general overview of crossmatching and the techniques utilized to treat patients to overcome sensitization barriers are presented in this topic review. A discussion of the diagnosis and treatment of acute antibody mediated rejection is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ABO DESENSITIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ABO incompatibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor outcomes combined with improvement in results using DDA limited ABOI transplantation in the United States in the past. However, an extreme lack of available deceased donor kidneys encouraged investigation into desensitization for",
"    <span class=\"nowrap\">",
"     ABOI/LDA",
"    </span>",
"    in Japan. Data from Japan demonstrating successful long-term results combined with subsequent successful short-term results from ABOI desensitization protocols in the United States and elsewhere have renewed interest in this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/3-9\">",
"     3-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     ABO blood groups and antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ABO blood group consists of four common categories (A, B, AB, and O), with types A and O most frequently found in the US population. Antigen is expressed on red blood cells, lymphocytes, and platelets, as well as epithelial and endothelial cells. Formation of blood group antibodies occurs against those antigens not native to the host. Thus antibodies to both A and B are found in an individual with blood type O, while an individual with blood type AB has no antibodies to A or B antigens. Given the distribution of blood group antigens in the US, the waiting time on the DDA list is markedly prolonged for patients with blood group B or O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood group A consists of two subtypes, A1 and A2. Approximately 80 percent of individuals in the US with blood group A express A1. The antigenic expression of A2 is quantitatively and qualitatively less than that of A1 and the overall immunogenic risk based on antigen expression alone is A1&gt;B&gt;A2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the lower immunogenic risk of the A2 antigen, donor A2 kidneys can generally be successfully transplanted into recipients with low pretransplant anti-A titers without the use of desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, blood group O individuals tend to have higher isoagglutinin antibody titers to both the A and B antigen, as compared to the formation of anti-B by blood group A individuals or anti-A by blood group B individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=see_link&amp;anchor=H2#H2\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'ABO (ABH) blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood type O recipients have a higher incidence of AMR following ABOI transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/16\">",
"     16",
"    </a>",
"    ]. The",
"    <strong>",
"     initial titer",
"    </strong>",
"    of the anti A or B isoagglutinin antibody rather than the antigen targeted (A1, A2 or B) was initially reported to correlate with the risk of AMR in such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/6,11,14,17,18\">",
"     6,11,14,17,18",
"    </a>",
"    ]. It is not clear whether the titer is as significant in the current era of immunosuppression. Most recently, the incidence of acute AMR after is 10 to 30 percent after ABOI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20757822\">",
"    <span class=\"h3\">",
"     ABOI protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two methods used to reduce circulating ABO antibody titers are plasmapheresis and immunoabsorption, with the goal of achieving titers &le;1:8 to 1:32, depending on center practice. Splenectomy and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have been used as adjunctive therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Long-term results in ABOI transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although higher rates of acute AMR are observed, long-term results of ABOI transplantation are comparable to those of ABO compatible transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/3,19-21\">",
"     3,19-21",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization protocols for",
"      <span class=\"nowrap\">",
"       ABOI/LDA",
"      </span>",
"      have been used since 1989 in Japan. One report detailed the long-term follow-up on 441 of 494 patients that received an ABOI renal allograft during the period of 1989 through 2001 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/3\">",
"       3",
"      </a>",
"      ]. In this retrospective multicenter analysis, there was no significant difference in patient or graft survival at year one, three, five, seven, or nine compared to historical data from 1055 recipients of ABO compatible living donor allografts.",
"     </li>",
"     <li>",
"      A single center report from Japan described marked improvement in ABOI graft survival in 117 patients in the 2000 to 2004 era, as compared to previous same-center results following the incorporation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      in the maintenance immunosuppression regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/19\">",
"       19",
"      </a>",
"      ]. In this analysis, statistically superior allograft survival in the most recent period was reported at one year (94 versus 78 percent) and five years (90 versus 73 percent); acute rejection rates had also markedly improved (15 versus 48 percent).",
"     </li>",
"     <li>",
"      The long-term outcomes of 60 consecutive ABOI kidney transplantations after the use of a protocol that incorporated antigen-specific immunoadsorption,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and IVIG were compared to that of 276 ABO compatible live donor transplant recipients in three centers in Sweden [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/20\">",
"       20",
"      </a>",
"      ]. At follow-up of up to 61 months, allograft survival was 97 percent for the ABOI group versus 95 percent for the ABO compatible recipients. Patient survival was identical for both (98 percent). At this time, isoagglutinin immunoadsorption filters are not approved for use in the United States; however, the outstanding initial results from this study are very encouraging and of extreme interest given the antigen specificity of this procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Outcomes of transplantation across both ABOI and HLA barriers are inferior to those of ABOI transplantation, with increased incidence of early and late acute cellular rejection and AMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Is splenectomy necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although controversial, splenectomy has been commonly used in desensitization protocols for ABOI transplantation to reduce the risk of AMR. This is particularly true in Japan where the majority of the experience and long-term data are available. Early reports describing hyperacute irreversible vascular rejection in recipients of an ABOI allograft not undergoing pretransplant splenectomy as compared to favorable outcomes in recipients that had been splenectomized promoted this practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]; in the United States, however, the combination of an additional surgical risk and an increased risk of serious infection, especially in the setting of chronic immunosuppressive therapy, has served to curtail enthusiasm for ABOI transplantation.",
"   </p>",
"   <p>",
"    The routine use of pretransplant splenectomy in ABOI transplantation has been called into question. One report described that the suppression of ABO antibodies after splenectomy is not significantly different than in ABOI recipients that are not splenectomized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newly described ABOI desensitization protocols with attention to pretransplant antibody titers using standard pre- and post-transplant antibody reduction with either plasmapheresis or immunoadsorption and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (to perform a partial pharmacologic splenectomy) may allow for the avoidance of a surgical splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/7,8,27\">",
"     7,8,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a humanized mouse monoclonal antibody that targets CD20, which is expressed on the majority of B cells. Rituximab has been reported to allow successful ABOI transplantation when added to a standard protocol in patients otherwise resistant to other desensitization procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/28\">",
"     28",
"    </a>",
"    ]. Despite an absence of detectable splenic B cells after rituximab administration, plasma cells remain, as the majority of plasma cells lack CD20 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. While the intact plasma cells are able to produce isoagglutinin antibodies, the deletion of plasma cell precursors may decrease the risk of AMR if used in conjunction with other antibody depleting measures.",
"   </p>",
"   <p>",
"    The specific dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    required in this setting is unclear. In a Japanese study, five ABOI renal transplant recipients received one dose of rituximab (at 10, 15, 35, 150, or 300",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    3 to 13 days before transplantation, while one patient did not receive rituximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/30\">",
"     30",
"    </a>",
"    ]. B cells were completely eliminated from the circulation within 30 days with every dose except for 10",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    given once. Single doses of 35",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    (approximately 100 mg as a single dose) or higher eliminated detectable splenic B cells.",
"   </p>",
"   <p>",
"    There is increasing evidence that splenectomy may be avoided in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report on six ABOI renal allograft recipients (from A1, A2 and B donors) describes successful transplantation and graft survival without any evidence of AMR through a median follow-up of one year despite the avoidance of splenectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/7\">",
"       7",
"      </a>",
"      ]. The desensitization protocol included plasmapheresis, IVIG and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and used daclizumab induction therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , MMF and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      maintenance therapy. Rituximab was also given as a one-time pretransplant dose of 375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      and anti-cytomegalovirus antibody immune globulin (CMVIVIG) was administered at a dose of 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      after each plasmapheresis session. Although any additional clinical benefit is uncertain, this form of IVIG is supplied by a stable pool of donors and has less chance for batch-to-batch immunologic variability than other pooled IVIG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As most AMR in the setting of ABOI transplantation has been reported to occur in the first several months post-transplantation, the authors of this study felt that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to provide several months of a partial pharmacologic splenectomy would prevent AMR and avoid the long-term risks of a surgical splenectomy. The number of plasmapheresis sessions and IVIG administrations was based on the isoagglutinin titer, and transplantation was not performed until the titer was &le;1:16. The highest pretransplant isoagglutinin titers present were in three patients with titers of 1:128. The median number of pretransplant plasmapheresis sessions was five and sessions were routinely continued on post-transplant day one, three and five.",
"   </p>",
"   <p>",
"    The patients ranged in age from 32 to 73 years (mean 58) and the mean follow-up serum creatinine concentration was 1.3 &plusmn; 0.1",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Isoagglutinin titers remained lower than pretransplant baseline. Protocol biopsies demonstrated one episode of cellular rejection and no histologic evidence of AMR. Of note, positive peritubular capillary (PTC) C4d staining was present in 10 of 15 cases. This approximates the percentage of C4d+ biopsies present in recipients of ABOI renal allografts at that institution when splenectomy has been employed rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar findings were noted in a study of 11 recipients of ABOI renal allografts that included A1 and B donors and a non-splenectomy protocol employing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and immunoadsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20758057\">",
"    <span class=\"h3\">",
"     Is rituximab necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens using plasmapheresis and low dose CMVIg alone may be equally effective compared to those involving splenectomy or anti-CD20 therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/21,31\">",
"     21,31",
"    </a>",
"    ]. In one single-center study, outcomes with initial ABOI protocols involving splenectomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pretransplant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in addition to plasmapheresis and IVIG (32 patients) were compared to their current protocol of plasmapheresis and IVIG alone (28 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/21\">",
"     21",
"    </a>",
"    ]. Graft survival and rates of antibody mediated rejection were similar in both groups.",
"   </p>",
"   <p>",
"    Although long-term follow-up is needed, these reports suggest that attention to the isoagglutinin titer at the time of transplantation and routine post-transplant antibody reduction with either plasmapheresis or immunoadsorption may significantly reduce the risk of AMR and allow for the elimination of splenectomy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    from the ABOI desensitization protocol.",
"   </p>",
"   <p>",
"    Most transplant centers in the United States and Europe presently avoid routine splenectomy prior to ABOI transplantation. However, splenectomy may remain an effective treatment for refractory antibody mediated rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/32\">",
"     32",
"    </a>",
"    ]. The utility of routine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administration remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     A question of accommodation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of detectable isoagglutinin titers, AB endothelial antigen expression and positive PTC C4d staining despite the absence of any histologic evidence of AMR has been thought to represent ABOI immunologic accommodation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of positive PTC C4d staining in ABOI transplantation has been described by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/6,34-36\">",
"     6,34-36",
"    </a>",
"    ], and appears to have a different connotation than when seen in the setting of AMR secondary to HLA incompatibility.",
"   </p>",
"   <p>",
"    Based upon the findings from one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/7\">",
"     7",
"    </a>",
"    ], the authors stated that they no longer recommend initiation of therapy targeting AMR based upon an isolated finding of positive PTC C4d staining in ABOI transplantation. When graft dysfunction secondary to AMR is present in the setting of ABOI transplantation, PTC C4d is likely to be positive, but histologic manifestations associated with AMR are also likely to be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another analysis found that C4d positive staining was present in 80 percent of protocol ABOI allograft biopsies and in 58 percent of ABOI biopsies performed for graft dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/35\">",
"     35",
"    </a>",
"    ]. There was no correlation between this finding and histologic evidence of antibody mediated rejection or graft injury. Although unable to ascertain with certainty given the small sample size in this analysis, positive C3d staining in ABOI allografts may correlate with antibody mediated graft injury. Whether the early presence of PTC C4d in these protocols impacts on long-term graft function remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Isoagglutinin antibody titers",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was initially reported that higher baseline isoagglutinin antibody titers predispose to an increased risk of antibody mediated rejection. It is unclear whether a significantly elevated baseline antibody titer predisposes to a poor long-term outcome, given initial successes through desensitization. Furthermore, although elevated isoagglutinin titers are generally observed during acute AMR, the positive predictive value of elevated posttransplant titers is poor, with high titers seen in otherwise stable ABOI recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a marked difference in the reporting of antibody titers among institutions. The classic tube dilution method is most commonly used to report an IgM isoagglutinin titer",
"    <strong>",
"     AND",
"    </strong>",
"    a total isoagglutinin titer. These have commonly been reported in the literature as an IgM and IgG titer, but actually represent IgM and total titer. In addition, given observer variation, the reported result should be considered an approximation. Thus, a titer reported at 1:128 may represent a titer of 1:64 to 1:256.",
"   </p>",
"   <p>",
"    Improved assays, such as ELISA based technology, should assist in helping to define and standardize acceptable IgM and IgG isoagglutinin titers at baseline and in the peritransplant period. Although center specific protocols vary, the total isoagglutinin antibody titer is generally reduced to at least 1:32 (and often to &le;1:8) before proceeding to transplantation, as higher titers are associated with acute AMR posttransplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most centers also use immunoadsorption or plasmapheresis to maintain an isoagglutinin titer &le;1:16 during the critical two week period following ABOI transplantation. If fresh frozen plasma (FFP) replacement is required as a result of plasmapheresis treatment, donor blood type or AB donor FFP should be given in order to avoid the administration of anti-allograft isoagglutinin antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, it is unclear which strategy, plasmapheresis, immunoadsorption, IVIG infusion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    , anti-IL-2 receptor antibody, splenectomy, anti-CD20 or a combination of therapies is more effective or cost effective than any of the others described in this section. Only a limited number of institutions have published their results, which are principally short term. While a variety of protocols seem to be effective in allowing successful transplantation across the blood group barrier, much work remains to determine optimal protocols, acceptable baseline and peri-transplant antibody titers, and to define the mechanisms responsible for this perceived process of accommodation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HLA SENSITIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Types and importance of anti-HLA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end stage renal disease that are broadly sensitized to HLA antigens via previously administered blood products, pregnancy, or prior transplantation often possess antibodies directed against deceased donor and potential living donor kidneys. Assays that define sensitization detect antibodies against the broad spectrum of potential donors. By comparison, the crossmatch identifies antibodies against a specific donor.",
"   </p>",
"   <p>",
"    Depending upon the assay used to detect sensitization or perform a crossmatch, different types of antibodies can be identified. The clinical relevance of the antibodies detected may vary, and in some cases is uncertain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG versus IgM &mdash; IgG antibodies detected by sensitization or crossmatch assays are generally considered to reflect true sensitization against HLA antigens, while IgM antibodies are not considered typical of a true anti-HLA response.",
"     </li>",
"     <li>",
"      T cell versus B cell &mdash; Antibodies detected against T cells have been generally considered to represent true anti-HLA sensitization against class I antigens. By comparison, T cell negative, B cell positive crossmatch results have been considered to represent HLA class II antibodies of less significance clinically. However, the realization that B cells also express HLA class I antigen at a level quantitatively greater than on T cells meant that low titers of preexistent HLA class I antibody, rather than only HLA class II antibody, could produce this result. Thus, T cell",
"      <span class=\"nowrap\">",
"       negative/B",
"      </span>",
"      cell positive reactions may be secondary to either class I or class II antibodies, while a T cell",
"      <span class=\"nowrap\">",
"       positive/B",
"      </span>",
"      cell negative reaction most likely results from a non-HLA antibody, as class I antigen is expressed on both T and B cells.",
"     </li>",
"     <li>",
"      Complement fixing versus noncomplement fixing &mdash; Antibodies that must fix complement to produce a positive assay are considered cytotoxic and likely to be of clinical importance. Antibodies detected by means that are independent of complement fixation, such as flow cytometric assays, or single-antigen bead assays, such as Luminex assays, may detect other antibodies that may not be cytotoxic and for which the clinical significance is unclear. While data do suggest that a positive flow crossmatch is associated with an increased risk of rejection and decreased graft survival, the positive predictive value of this assay is likely dependent upon whether or not donor specific antibodies are present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/38\">",
"       38",
"      </a>",
"      ] and, if so, whether the antibody is able to fix complement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most assays detect the presence of antibody but not the precise HLA specificity. Assays to identify the specific HLA antigens targeted, such as single-antigen bead assays like the Luminex assay, require additional time to perform, and can only be undertaken in settings such as living donor allograft (LDA), when time constraints are not an issue.",
"   </p>",
"   <p>",
"    Transplantation should",
"    <strong>",
"     not",
"    </strong>",
"    proceed if there is evidence of a positive crossmatch secondary to a cytotoxic IgG anti-HLA antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Determination of sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different assays are available to help determine how sensitized a potential transplant recipient is to HLA antigens. Depending upon the institutional preference, at least one of these tests is performed at the time of the initial transplant evaluation. Patient sensitization is classically reported as the percent Panel Reactive Antibody (PRA) and is an estimate of the likelihood of a positive crossmatch to a pool of potential donors.",
"   </p>",
"   <p>",
"    The PRA is reported as historical (the highest value recorded on previous testing) and as current PRA. When using cytotoxicity assays, the percent PRA may vary from one testing date to another in an individual patient secondary to either a change in antibody levels in the potential recipient, or a change in the composition of HLA antigens in the assay utilized. Enzyme linked immunoadsorption assays (ELISA) and flow",
"    <span class=\"nowrap\">",
"     cytometry/flow",
"    </span>",
"    bead technology can also be used to estimate PRA using a fixed composition of HLA antigens.",
"   </p>",
"   <p>",
"    In 2007, data from the United States reported that 22 percent of patients on the kidney waiting list had a PRA of 10 to 79 percent and 16 percent were highly sensitized (as defined by a PRA &ge;80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different assays that can be used to determine the PRA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complement dependent cytotoxicity (CDC) assay estimates PRA by adding potential recipient serum to microtiter plates that contain a pool of lymphocytes with defined HLA antigens. Rabbit complement is added and the plates are viewed after addition of a vital stain. The PRA can then be determined based upon the number of cytotoxic reactions that are observed.",
"     </li>",
"     <li>",
"      The enzyme-linked immunoabsorption (ELISA) assay uses microtest trays containing known HLA antigens to which potential recipient serum is added. This test is more rapid than the CDC assay and the HLA antigens used for screening can be adjusted as necessary to reflect the presumed potential donor pool.",
"     </li>",
"     <li>",
"      The PRA can also be estimated using flow cytometry, using defined HLA \"flow beads\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/41\">",
"       41",
"      </a>",
"      ]. Flow cytometry measures the fluorescence after patient serum has been added to a defined set of HLA antigen flow beads and a positive test is determined by the mean channel shift in intensity. Highly sensitized patients are not included in a match run if the donor possesses antigens against which the recipient has preformed antibody, thereby increasing the probability of a negative final crossmatch. Multiplexed particle-based flow cytometric (Luminex) and ELISA based assays are increasingly used to detect the presence of HLA antibodies and donor specific antibodies and facilitate a \"virtual crossmatch\" which are now entered into the UNOS database at the time of listing for transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Algorithms employing such a \"virtual crossmatch\" can improve efficiency by decreasing the risk of a subsequent positive final crossmatch. The use of very sensitive assays to determine the presence of HLA antibodies may also improve outcomes by avoiding transplantation against the defined antigens, should the final crossmatch be negative. However, this is likely to be a patient and antigen-specific event. Antibodies detectable only by flow beads or other sensitive assays prior to transplantation may not always denote poor graft outcome and could result in an unnecessary bias against some potential recipients. The degree of ischemic injury and subsequent increased antigen expression may also impact the risk of acute and chronic antibody mediated rejection in this setting. At present, the long-term effects on graft function and the risk of acute or chronic antibody mediated rejection in the setting of a \"positive virtual crossmatch only\" transplant are unknown and require clarification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Crossmatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a potential donor is identified, a crossmatch is performed prior to transplantation to evaluate for any evidence of preformed antibodies with specificity for the potential donor that could lead to hyperacute or acute antibody mediated rejection. The available crossmatch assays differ in the degree of sensitivity.",
"   </p>",
"   <p>",
"    Transplant centers may adopt a conservative crossmatch policy wherein",
"    <strong>",
"     all",
"    </strong>",
"    testing is done using a very sensitive assay, such as flow cytometry. This may help to significantly reduce the chance of post-transplant hyperacute or acute rejection.",
"   </p>",
"   <p>",
"    However, as noted above, this approach may also be too sensitive in that clinically irrelevant, non-HLA antibodies are detected and potentially viable transplant opportunities are bypassed. Thus, many centers use an approach that matches the crossmatch assay to the clinical concern given the potential for sensitization in the potential recipient. With this strategy, flow cytometry is used only in specific cases. This remains a controversial area.",
"   </p>",
"   <p>",
"    The pretransplant crossmatch may be performed using three different sets of sera from the same potential recipient against the donor lymphocytes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum from the potential recipient at the time of the highest historical PRA",
"     </li>",
"     <li>",
"      Serum from the potential recipient that was most recently stored",
"     </li>",
"     <li>",
"      Serum that is obtained when the patient is called in for a potential transplant (final crossmatch)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The final crossmatch (from fresh serum) is done in",
"    <strong>",
"     all",
"    </strong>",
"    cases and must be negative to proceed with transplantation. The scenario of current sera negative, historical sera positive may indicate the presence of preformed antibodies that have waned in titer, but also the presence of a memory cell line that could rapidly expand and produce rejection if rechallenged with donor antigen. Although this is not an absolute contraindication to proceeding with transplantation, it should be evaluated in the clinical context of presumed patient risk and with close post-transplant monitoring. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following is an overview of the different types of crossmatch tests and the significance of their results:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complement dependent cytotoxicity (CDC or standard NIH-CDC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement dependent cytotoxicity (CDC) or standard National Institute of Health (NIH)-CDC is similar to the CDC test used to define PRA. It is performed using wells containing donor cells rather than a pool of lymphocytes. Potential recipient serum is added along with rabbit complement and cytotoxicity is determined after administration of a vital dye. The test is done in dilutions to rule out prozone effect and to help estimate the magnitude of the immunologic reaction.",
"   </p>",
"   <p>",
"    Modifications of this test include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A wash step to help eliminate clinically irrelevant antibodies (Amos-modified CDC)",
"     </li>",
"     <li>",
"      The addition of antihuman globulin (AHG-modified CDC) to increase the sensitivity by inducing cross linking of any antibody present and thus increasing the likelihood of visualizing cytotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the crossmatch is positive by CDC, the process is repeated with the addition of Dithiothreitol (DTT). This step",
"    <strong>",
"     reduces",
"    </strong>",
"    the disulfide bonds present when the antibody is IgM. A test that is CDC",
"    <span class=\"nowrap\">",
"     positive/DTT",
"    </span>",
"    negative (presence of an IgM antibody only) should",
"    <strong>",
"     not",
"    </strong>",
"    preclude transplantation. By comparison, the presence of a CDC",
"    <span class=\"nowrap\">",
"     positive/DTT",
"    </span>",
"    positive test is an indication of IgG anti-donor antibody and is a",
"    <strong>",
"     contraindication",
"    </strong>",
"    to transplantation without the use of a desensitization procedure, especially if a donor specific antibody has been defined. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow cytometry can be used as a crossmatch test and is routinely performed in some institutions but only selectively in others. As an acute screening test for DDA, it can define a positive T or B cell reaction and whether the antibody present is an IgG or an IgM; however, this may potentially result from non-HLA antibody. In the setting of LDA, when acute results are not necessary, flow beads or other sensitive single antigen antibody detection methods can be used to determine if an IgG HLA antibody is responsible for the registered shift in fluorescent intensity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ELISA test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ELISA test can be used post-transplant to rapidly determine the presence of donor specific antibodies (DSA). However, it cannot be used as a pretransplant crossmatch test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of highly sensitive screening techniques, particularly the",
"    <strong>",
"     single antigen-bead",
"    </strong>",
"    assay, have been introduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. With this technique, microspheres coated with single HLA antigens are incubated with patient sera, resulting in the detection of both complement and non-complement activating antibodies.",
"   </p>",
"   <p>",
"    These assays are helpful in determining the etiology of a positive crossmatch test, but as above, the clinical relevance in the setting of a negative crossmatch is unclear. The presumed strength of an antibody compared to a control and prior antigen exposure history should be considered prior to transplantation in the setting of detectable DSA but negative cytotoxicity crossmatch. If performed, close monitoring should ensue post-transplant, given a presumed increased risk of antibody mediated rejection. As with transplantation after HLA desensitization, long-term results of this practice are unknown.",
"   </p>",
"   <p>",
"    Sensitive single antigen assays are also useful for listed patients with persistently positive crossmatch results against deceased donors. Evidence for a lack of DSA on recent recipient screening tests can allow transplantation to proceed when positive crossmatch results occur as a result of autoantibodies or other non-HLA antibodies (negative virtual crossmatch).",
"   </p>",
"   <p>",
"    The advent of these assays has been extremely useful and as above, has been incorporated into the UNOS organ-allocation schema, but work remains to determine the significance of positive DSA results in an individual setting and the expected outcome in a desensitization protocol. Further endeavors will include comparing in-vitro results to in-vivo events, as not every antibody detected is necessarily expressed or accessible in-vivo and may be irrelevant. Likewise, complement activation is not required for a positive test result, and the significance of non-complement activating antibodies in-vivo is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     What we test",
"    </span>",
"    &nbsp;&mdash;&nbsp;We routinely perform an NIH-CDC T and B-cell AHG crossmatch on all allograft recipients. In addition, we perform a T and B-cell flow crossmatch on potential recipients with a second transplant (who are presumed to be highly sensitized) or with a history of a positive PRA as detected by either ELISA or standard CDC assays. A flow crossmatch is also performed in the setting of any high risk case for presensitization (child to mother or husband to wife donation).",
"   </p>",
"   <p>",
"    We currently use single-antigen bead assays (Luminex) to test for HLA antibodies in potential DDA recipients and to assess donor specific antibodies in potential LDA recipients. Any potential LDA recipient with evidence of donor specific antibodies undergoes a flow crossmatch in addition to the cytotoxicity crossmatch. All of this information is used to help define the presumed risk of AMR and plan for desensitization, if appropriate, or to recommend against transplantation with a particular donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary and risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the test used, highly sensitized patients are often crossmatch positive to multiple potential donors and require a zero antigen mismatch allograft to increase success. These patients are therefore relegated to the deceased donor waiting list and have a very low rate of eventual transplantation. For this reason, desensitization against preformed HLA antibodies is being used for both DDA and LDA recipients.",
"   </p>",
"   <p>",
"    The following is a summary of the contraindications for transplantation and a proposal for risk assessment for acute antibody mediated rejection based on crossmatch results, as determined by the Profiling Work Group for AMR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A current positive CDC or AHG-CDC is associated with a high risk for antibody mediated rejection (AMR).",
"     </li>",
"     <li>",
"      A current positive CDC is a contraindication to transplantation, unless donor specific antibodies (DSAs) can be reduced with desensitization protocols.",
"     </li>",
"     <li>",
"      A current positive flow crossmatch or a remote (historic) positive CDC or AHG-CDC crossmatch is associated with an intermediate risk for AMR. In this setting, augmented immunosuppression may be required.",
"     </li>",
"     <li>",
"      A low risk is noted in patients with negative current and remote flow or AHG-CDC crossmatch. Such patients can undergo conventional immunosuppressive therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current and remote negative crossmatches, if obtained only by CDC, are not necessarily associated with a low risk for AMR given the highly variable sensitivity of the CDC technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DESENSITIZATION PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, variations of two protocols are principally used in an attempt to desensitize potential recipients with preformed HLA antibodies and allow a successful transplant across this barrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desensitization can be used for a potential recipient of a LDA with DSA in an attempt to reduce the level of those specific antibodies. It can also be used for an individual on the deceased donor allograft waiting list broadly sensitized to HLA antigens (PRA &ge; approximately 30 percent) with repeated positive crossmatch results.",
"   </p>",
"   <p>",
"    One method uses high dose IVIG and the other uses low dose IVIG and plasmapheresis in a protocol essentially identical to that previously described for ABOI transplantation.",
"   </p>",
"   <p>",
"    Monitoring for AMR post-transplantation consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Laboratory evaluation",
"     </li>",
"     <li>",
"      Monitoring DSA titers",
"     </li>",
"     <li>",
"      Protocol and for-cause biopsies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Use of IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pooled immune globulins likely have multiple mechanisms of action that are of relevance in modulating the immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. These include neutralizing the presence of anti-idiotypic antibodies, a reduction in antibody formation, inhibition of complement-dependent injury and other immunomodulatory actions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Several reports describe successful use of IVIG in HLA desensitization protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]. Intravenous immunoglobulins have also been used in the treatment of biopsy proven AMR independent of desensitization and in cases of steroid and antilymphocyte globulin resistant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/54,60-62\">",
"     54,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal dosing and frequency of administration of IVIG in either the high or low dose protocol is unclear and the optimal regimens remain to be defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     High dose IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high dose IVIG for desensitization was initially reported in the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Protocols typically involve monthly infusions of IVIG at 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum 140 g). Subsequently, other reports of successful use of this protocol to desensitize both living donor recipients and patients on the deceased donor waitlist have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/58,65\">",
"     58,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first of these reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/65\">",
"     65",
"    </a>",
"    ], 15 patients with either a panel reactive antibody (PRA) of &gt;50 percent or with a positive crossmatch to their potential living donor were given 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of IVIG monthly for three months. Thirteen of the 15 showed evidence of desensitization (reduction of PRA by at least 50 percent or a repeat negative crossmatch to the living donor) and underwent renal transplantation (11 DDA and 2 LDA). The mean decrease in PRA for recipients of a DDA was 80 percent and a post-IVIG administration NIH cytotoxicity crossmatch was negative prior to transplantation. The IVIG was repeated at the same dose on post-transplant day zero and one. Thymoglobulin was used for induction and maintenance immunosuppression consisted of MMF, corticosteroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . The IVIG was again repeated at post-transplant day 20 or 21 and 40 or 41.",
"   </p>",
"   <p>",
"    The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One graft was lost secondary to thrombosis and one graft was lost secondary to rejection.",
"     </li>",
"     <li>",
"      No other episodes of rejection were reported in the remaining allografts during follow-up of over one year.",
"     </li>",
"     <li>",
"      The success rate for desensitization was higher than that reported previously by the same group (87 percent versus 50 percent) and was attributed to a lower dose of IVIG administered in the earlier trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the other reported analysis of desensitization using high dose IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/58\">",
"     58",
"    </a>",
"    ], 45 patients highly sensitized to HLA antibody (15 DDA, 28 LDA, and 2 cardiac transplant patients) underwent a similar protocol. The 15 potential DDA recipients all had exhibited a positive crossmatch to multiple potential donors and had been on dialysis for greater than five years. The 28 potential LDA recipients all had a positive crossmatch with their respective donor. The two potential cardiac transplant recipients were also highly HLA sensitized.",
"   </p>",
"   <p>",
"    The potential LDA recipients underwent an initial in vitro cytotoxicity test to evaluate the inhibition or reduction of DSA. If the in vitro test demonstrated inhibition, the recipient was given IVIG at a dose of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum dose of 140 g). If the repeat crossmatch test was negative or the reaction significantly decreased, the transplantation was performed within 24 to 72 hours. An additional dose of IVIG at 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    was administered one month after transplantation. 26 of the 28 potential LDA recipients exhibited an acceptable crossmatch after only one dose of IVIG. The remaining two patients required three additional monthly doses to achieve an acceptable crossmatch.",
"   </p>",
"   <p>",
"    For potential deceased donor kidney or cardiac recipients, the PRA test was repeated in the presence of IVIG. If the percent PRA was significantly decreased, the patients received 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of IVIG monthly for four months. Sixteen of the 17 patients in this category underwent transplantation (12 kidneys, one cardiac-liver, one cardiac-kidney, one liver-kidney, and one cardiac). Ten of these had a negative cytotoxicity crossmatch and negative flow cytometry to the potential donor at the time of transplantation and six of these had a negative cytotoxicity crossmatch, but a positive flow cytometry at the time of transplantation. Intravenous immunoglobulin at a dose of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    was initiated prior to the surgery and continued intraoperatively. Potential LDA recipients with a positive in vitro crossmatch despite IVIG or non-LDA recipients not exhibiting a reduction in PRA were not considered for transplantation. All recipients in this protocol received induction with daclizumab and were maintained on corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF.",
"   </p>",
"   <p>",
"    The results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirteen of the 42 recipients (31 percent) had an episode of acute rejection (all within two months post-transplant) and three grafts were lost to rejection. Recurrent rejection was unusual.",
"     </li>",
"     <li>",
"      The mean serum creatinine at two years was 1.4",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      (124",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      with a patient survival of 98 percent and a graft survival of 89 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large placebo controlled trial among highly sensitized patients awaiting kidney transplantation also found that high dose IVIG therapy successfully reduced anti-HLA antibody levels, thereby improving transplantation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/66\">",
"     66",
"    </a>",
"    ]. In this multicenter study, 101 patients with PRAs &ge;50 percent were randomly assigned to IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    monthly for four months) or placebo. Active therapy significantly reduced PRA levels and increased the transplantation rate (35 versus 17 percent for placebo). Although rejection episodes were more common among the IVIG group, allograft survival rates at a median period of two years post-surgery were similar in both groups (80 and 75 percent for IVIG and placebo, respectively).",
"   </p>",
"   <p>",
"    This same group of investigators found that the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to a high dose IVIG regimen was safe and effective in lowering PRA levels and increasing transplantation rates among highly sensitized patients. In their initial published experience, 20 highly sensitized patients received IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    on day 0 and 30) plus rituximab (1 g on day 7 and 22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/67\">",
"     67",
"    </a>",
"    ]. After receiving this regimen, patients were eligible for kidney transplantation from either a living or deceased donor. With this approach, 16 of 20 patients were able to undergo transplantation using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    induction. The combination regimen decreased the PRA from 77 to 44 percent and lowered the mean time to transplantation from 144 to five months. The acute rejection rate was 50 percent; however most episodes were reversible and at one year, the mean serum creatinine concentration was 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    with patient and allograft survival rates of 100 and 94 percent, respectively.",
"   </p>",
"   <p>",
"    In a follow-up study by the same group, a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (1 g day 15) was administered with high-dose IVIG 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (days 1 and 30) to 76 HLA sensitized patients (75 percent with PRA &ge;80 percent). Using single dose rituximab, class I and II PRA, T and B-cell flow CXM MCS (LD) were significantly reduced, and transplantation was achieved in all patients. Thirty-seven percent of patients had acute rejection; 78 percent of these were antibody-mediated. However, similar to their initial findings, 24-month patient and graft survival rates of 95 and 84 percent were achieved, with 12-month mean creatinine levels of 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short-term effectiveness of high dose IVIG therapy appears to be the same with induction therapy with rabbit-antithmocyte globulin, Thymoglobulin&reg; versus that associated with daclizumab. A retrospective study found similar allograft survival rates as well as incidence of antibody mediated rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Summary &mdash; Advantages of the high dose IVIG method include the ability to desensitize patients on the DDA waiting list as well as potential LDA recipients. This protocol is much less resource intense and less expensive than low dose IVIG plus plasmapheresis protocols. Patients on hemodialysis can also receive monthly IVIG infusions while undergoing dialysis treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of the high dose IVIG protocol include a current lack of significant experience in either ABOI or in patients with known high titer HLA DSA. Crossmatch monitoring and monitoring of post-transplant DSAs for approximately three weeks after high dose IVIG administration is limited to the less sensitive NIH-CDC assay secondary to interference of high dose IVIG with other more sensitive assays.",
"   </p>",
"   <p>",
"    With the requirement to use the less sensitive NIH-CDC assay for crossmatch screening rather than the more sensitive AHG-cytotoxicity assay, one could infer that the recipients in the high dose IVIG protocols are likely to be more sensitized (false negative crossmatch) and thus at higher risk of rejection than those in the low dose IVIG protocols, which uses the AHG assay.",
"   </p>",
"   <p>",
"    Infusion of high dose IVIG may result in side effects such as headache, fever, muscle pain, shortness of breath, and chest discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/70\">",
"     70",
"    </a>",
"    ]. Complications can be minimized or eliminated by using products with an osmolality that approximates that of plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/48\">",
"     48",
"    </a>",
"    ]. Administering the necessary volume of an iso-osmolar IVIG solution while the patient is on dialysis allows for simultaneous correction of volume issues. When administering high dose IVIG to a patient not receiving simultaneous hemodialysis, individual product guidelines for rate of administration should be followed to decrease the risk of complications related to a high osmotic load. These complications can generally be avoided by using a non-sucrose based, iso-osmolar product.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Low dose IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization using a low dose IVIG protocol in combination with antibody reduction via plasmapheresis in renal transplantation was initially described by two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. The low dose IVIG protocol for HLA desensitization is essentially identical to that described previously for ABOI. It has been used to simultaneously cross both barriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternate day plasmapheresis is used pretransplantation with 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG (or CMVIG depending on the institutional protocol) administered after each session. The number of pretransplant treatments is estimated based on the baseline anti-HLA antibody titer.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    and MMF may be started with initiation of plasmapheresis depending on institutional protocol. Once the antibody is no longer detectable and the pretransplant AHG cytotoxicity crossmatch is negative, transplantation proceeds. Centers may continue plasmapheresis routinely posttransplant for a pre-specified number of treatments, or reserve for treatment of acute AMR alone.",
"   </p>",
"   <p>",
"    Some centers elect to proceed with transplantation despite the persistence of a low cytotoxicity antibody titer, generally &le;1:4. The advisability of transplantation in this setting remains to be determined, as the risk of rejection and early graft loss may be substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/72\">",
"     72",
"    </a>",
"    ]. The allowable risk, as determined by the titer of a persistent DSA, is currently a case-specific and transplant center dependent decision.",
"   </p>",
"   <p>",
"    Albumin is generally used for replacement in plasmapheresis in most desensitization protocols. This avoids the potential for HLA sensitization when using fresh frozen plasma (FFP). Two to three units of FFP may be substituted at the end of the treatment in lieu of albumin in the setting of a significantly increased PT or PTT, decreased fibrinogen level, or within 24 hours of a renal biopsy or other invasive procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one protocol using CMVIVIG, daclizumab was used for induction and maintenance therapy consisting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , MMF, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/54\">",
"     54",
"    </a>",
"    ]. Plasmapheresis and CMVIVIG were continued postoperatively on an alternate day regimen with the duration dependent on the pretransplant titer or as indicated by evidence of AMR. A follow-up report by the same group on 49 patients undergoing the low dose IVIG protocol described the absence of detectable DSA in 89 percent of recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up of patients treated with alternate day plasmapheresis and low-dose IVIG suggests a significant benefit to desensitization by this method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/74\">",
"     74",
"    </a>",
"    ]. Patient survival of 211 HLA-sensitized patients who were transplanted after treatment with plasmapheresis and low-dose IVIG was compared to that of matched control patients on a kidney transplantation waiting list who were undergoing dialysis (dialysis group). Patient survival was also compared to a matched control group of patients who were either on dialysis or started on dialysis and then underwent transplantation with an HLA-compatible kidney during the study period. The desensitization protocol included approximately 4 plasmapheresis sessions before and 5 after transplantation. Survival in the desensitized group was better at 3, 5 and 8 years (86, 81 and 81 percent) compared to patients in the dialysis group (67, 52 and 31 percent) and to patients in the dialysis-or-transplantation group (77, 66, and 49 percent).",
"   </p>",
"   <p>",
"    Another study described 14 patients with a positive AHG cytotoxicity crossmatch to a potential living donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients underwent plasmapheresis on days four, three, and one pretransplant, on the day of transplantation, and on day one and three post-transplantation. Intravenous immunoglobulin 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (non-CMVIVIG) was administered after each plasmapheresis session.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    at a dose of 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    was given on post-transplant day four. Splenectomy was performed at the time of transplantation in those with an intact spleen (two had previously been splenectomized). Thymoglobulin was used for induction and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , MMF and corticosteroids were used for maintenance therapy. The following were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient survival at a mean follow-up of 448 days was 86 percent. Two grafts were lost secondary to chronic allograft nephropathy following AMR and one functioning graft was lost secondary to patient death.",
"     </li>",
"     <li>",
"      The mean serum creatinine concentration was 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (124",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and all creatinine concentrations are &le;2.0",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      (.177",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Histologic evidence of AMR occurred in 6 of 14 patients (43 percent). The risk of AMR was related to the baseline anti-HLA antibody titer. Ten of the 14 recipients had baseline anti-HLA titers &le;1:4 and subclinical rejection was found in only two of these on protocol biopsy. The remaining four episodes of AMR (two subclinical) were present in recipients with baseline titers &ge;1:8.",
"     </li>",
"     <li>",
"      Both clinical and subclinical AMR was treated with pulse steroids, plasmapheresis, and IVIG. All four subclinical episodes responded to treatment and follow-up protocol biopsies showed no histologic evidence of rejection. Both episodes of rejection defined as clinically significant AMR demonstrated evidence of chronic allograft nephropathy on subsequent biopsies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate publication, none of the recipients had a positive AHG crossmatch at four months post-transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/75\">",
"     75",
"    </a>",
"    ]. However, 9 of 11 recipients tested using a sensitive single antigen flow bead assay did demonstrate persistent low levels of DSA.",
"   </p>",
"   <p>",
"    European studies using immunoadsorption combined with Thymoglobulin induction along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids, and MMF as maintenance therapy has also been used for desensitization in sensitized DDA recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In one analysis of 20 DDA recipients using immunoadsorption immediately prior to and in the post-transplant period for a median of 11 sessions, the 12-month patient survival was 95 percent and the graft survival was 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/76\">",
"     76",
"    </a>",
"    ]. Immunoadsorption is not yet routinely available in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Summary &mdash; Advantages of the low dose IVIG protocol include its documented use in patients with high titer anti-HLA antibodies with desensitization and successful transplantation in patients with DSA titers of up to 1:256 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/73\">",
"       73",
"      </a>",
"      ]. Although patients with high titer DSA may respond to this protocol, numerous pretransplant sessions may be required to obtain an adequately low titer that will allow successful transplantation across the HLA barrier as well as numerous post-transplant sessions to limit the rise of DSA titers and prevent AMR. As with the ABOI protocol, the number of pretransplant plasmapheresis sessions required can usually be estimated based on the initial antibody titer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When using low dose IVIG, the more sensitive AHG crossmatch can be used prior to transplantation, which may help detect the presence of preformed antibodies missed using the NIH cytotoxicity assay. After transplantation, it is possible to follow crossmatch and DSA by several assays, rather than only by the least sensitive NIH cytotoxicity assay.",
"   </p>",
"   <p>",
"    Interference of these tests by adjunct agents, such as Thymoglobulin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , requires special steps to remove the administered antibody from the assay to avoid false-positives. Accidental removal of anti-HLA antibody when attempting to remove Thymoglobulin or rituximab from the crossmatch assay could therefore result in a false negative. Disadvantages include the high financial cost and resource requirements to perform this desensitization protocol. As the timing of the actual transplant procedure must be adjusted to allow for an acceptable antibody titer, this protocol is only suitable for potential sensitized recipients of a LDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one study has directly compared high dose IVIG with",
"    <span class=\"nowrap\">",
"     plasmapheresis/low",
"    </span>",
"    dose IVIG protocols. The plasmapheresis regimens provided significantly better outcomes, although the study has significant limitations. In this report from the Mayo Clinic, the following three protocols were employed sequentially in renal transplant recipients with high DSA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasmapheresis plus low dose IVIG plus anti-CD20 antibody (32 patients), referred to as the plasmapheresis group. 19 of the 32 patients in this group also underwent splenectomy; post-transplant plasmapheresis and low dose IVIG were continued on post-surgery days one to three for a total of two to three sessions.",
"     </li>",
"     <li>",
"      High single dose IVIG (13 patients), which is the high dose IVIG group",
"     </li>",
"     <li>",
"      Plasmapheresis plus low dose IVIG plus anti-CD20 antibody plus pretransplant Thymoglobulin combined with post-transplant DSA monitoring (16 patients), which is the",
"      <span class=\"nowrap\">",
"       plasmapheresis/monitoring",
"      </span>",
"      group. Post-operative plasmapheresis and low dose IVIG were continued on post-transplant days one through three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Achieving a negative crossmatch was significantly more likely with both plasmapheresis protocols versus high dose IVIG (84, 88, and 38 percent for the plasmapheresis,",
"    <span class=\"nowrap\">",
"     plasmapheresis/monitoring,",
"    </span>",
"    and high dose IVIG groups, respectively).",
"   </p>",
"   <p>",
"    However, the significantly lower response rate in this report with high dose IVIG may have resulted from the lack of in vitro testing of patients in the high dose IVIG group to identify potential responders prior to systemic administration of IVIG. Patients with low baseline antibody titers (&le;1:4), were successfully desensitized by any of the three methods. By comparison, only two of ten patients with a baseline titer &ge;1:8 were successfully desensitized with the high single dose protocol versus twelve of nineteen in the",
"    <span class=\"nowrap\">",
"     plasmapheresis/low",
"    </span>",
"    dose IVIG groups. Three of the eight patients not responding to the high dose IVIG regimen did respond when switched to the",
"    <span class=\"nowrap\">",
"     plasmapheresis/low",
"    </span>",
"    dose IVIG protocol. Only one of ten patients with a baseline titer &ge;1:32 responded to any of the three methods. Significantly lower humoral rejection rates were also reported with the plasmapheresis protocols (37, 29, and 80 percent, respectively), although none of the patients in the high single dose IVIG group received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or post-transplant administration of IVIG.",
"   </p>",
"   <p>",
"    Another possible explanation for the lower likelihood of a negative crossmatch result with the high dose IVIG protocol in this analysis as compared to previous high dose IVIG desensitization reports may have been the use of the AHG cytotoxicity assay. The increased sensitivity of the AHG-CDC assay as compared to the standard CDC assay used in previous high dose IVIG reports may have produced a greater number of persistent positive crossmatch results.",
"   </p>",
"   <p>",
"    Additional limitations with this study include nonrandomization and low numbers of patients. While this report suggests that plasmapheresis-based desensitization protocols may provide superior desensitization outcomes and lower rates of acute antibody mediated rejection as compared to a high single dose IVIG regimen, the avoidance of pretransplant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and absence of post-transplant administration of IVIG in the single dose group may have biased the results.",
"   </p>",
"   <p>",
"    Patients with low baseline antibody titers responding to high dose IVIG may do equally as well with further optimization of therapy. However, whether or not the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or the routine post-transplant administration of IVIG would be of benefit in reducing the incidence of acute rejection in a high dose IVIG protocol is unclear at this time.",
"   </p>",
"   <p>",
"    The utility of routine post-transplant plasmapheresis and low dose IVIG administration in response to rising DSA titers in unclear. In this analysis, DSA monitoring with reinitiation of",
"    <span class=\"nowrap\">",
"     plasmapheresis/IVIG",
"    </span>",
"    delayed the onset of, but did not reduce the incidence of antibody mediated rejection. Routine post-transplant plasmapheresis and IVIG administration for one to three sessions, as described in this study, in the absence of graft dysfunction or evidence of rejection, is of uncertain benefit.",
"   </p>",
"   <p>",
"    Given the high risk of acute rejection, however, most clinicians would favor this approach until more data are available. Subsequent treatments are then based upon results of protocol or indication biopsies. However, a rising DSA titer in the early post-transplant setting should prompt an allograft biopsy and suggests the need for intensification of therapy, in the absence of graft dysfunction; reinitiation of",
"    <span class=\"nowrap\">",
"     plasmapheresis/IVIG",
"    </span>",
"    or other treatment should be based on biopsy results.",
"   </p>",
"   <p>",
"    The need for a completely negative crossmatch versus reduction to a low titer antibody response prior to attempting transplantation has been debated. The authors of this study describe their experience transplanting across a low titer positive crossmatch following desensitization, in which seven of ten patients had acute antibody mediated rejection and five of ten had early graft loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the results of the previous comparative study and the lack of long-term data or late protocol biopsy information for HLA desensitization, the following generalized recommendations can be made pending further investigations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A negative crossmatch is desirable in desensitization protocols. Transplantation in the setting of even a low titer positive crossmatch may significantly increase the risk of early graft loss and require prolonged, intense post-transplant therapy with uncertain long-term results.",
"     </li>",
"     <li>",
"      Desensitization attempts in the patient with higher baseline titer HLA antibodies (&ge;1:32) may be very resource intense with a low likelihood of producing a completely negative crossmatch. Transplantation attempts following a desensitization protocol in these patients likely carry with it an increased risk of repeated episodes of antibody mediated rejection and early graft loss.",
"     </li>",
"     <li>",
"      Single, high-dose IVIG desensitization protocols may be useful in patients with low baseline antibody titers (&le;1:4) and optimization of therapy may allow for a reduced incidence of acute antibody mediated rejection.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Plasmapheresis/low",
"      </span>",
"      dose IVIG is more likely to produce a negative crossmatch in patients with mid-level titers (1:8 to 1:16) of HLA antibodies than is single high dose IVIG. Optimal post-transplant monitoring and timing of reinitiation of therapy remains to be determined.",
"     </li>",
"     <li>",
"      A high risk of acute rejection and increased risk of early graft loss along with uncertain long-term outcome is present with any HLA desensitization protocol and this information should be understood by both donor and recipient prior to proceeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment of AMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have undergone transplantation using HLA desensitization should be considered at high risk for antibody mediated rejection. As a result, there is a low threshold for biopsy (",
"    <a class=\"graphic graphic_algorithm graphicRef55208 \" href=\"mobipreview.htm?33/47/34558\">",
"     algorithm 1",
"    </a>",
"    ) and protocol biopsies (",
"    <a class=\"graphic graphic_algorithm graphicRef76257 \" href=\"mobipreview.htm?11/53/12126\">",
"     algorithm 2",
"    </a>",
"    ) are performed on these allografts, independent of evidence of clinical allograft dysfunction.",
"   </p>",
"   <p>",
"    Therapy is based in part on the time of AMR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early post-transplant setting in these patients, treatment including IVIG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasmapheresis is commonly initiated based on positive C4d staining or evidence of DSA alone, independent of histologic findings. Unlike the case with C4d staining in ABOI transplantation, positive C4d staining is much more likely to be associated with antibody mediated rejection in the setting of HLA desensitization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/35\">",
"       35",
"      </a>",
"      ]. Treatment for apparent AMR is essentially the same as for desensitization, although the duration of plasmapheresis and IVIG is dependent upon an improvement in renal function and a decrease in the titer of DSA.",
"      <br/>",
"      <br/>",
"      Other rescue therapies, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , splenectomy, the terminal complement inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      , or the proteosomal inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      have been used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/32,78-80\">",
"       32,78-80",
"      </a>",
"      ]. In a single-center study that compared high dose IVIG alone (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      x 4 doses) to four sessions of",
"      <span class=\"nowrap\">",
"       plasmapheresis/low-dose",
"      </span>",
"      IVIG + 2 doses of rituximab",
"      <span class=\"nowrap\">",
"       (375mg/m2)",
"      </span>",
"      for treatment of AMR, graft survival at 36 months was significantly higher in the",
"      <span class=\"nowrap\">",
"       plasmapheresis/low-dose",
"      </span>",
"      <span class=\"nowrap\">",
"       IVIG/rituximab",
"      </span>",
"      group compared to the high-dose IVIG alone group (91.7 versus 50 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the late post-transplant course, C4d",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DSA may be present in the absence of graft dysfunction. The implications of these findings are not clear. In this setting, hypervigilance with potential modification of maintenance immunosuppression is the norm, rather than initiating intensive therapy using IVIG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasmapheresis. Subclinical rejection (as defined by positive C4d staining associated with histologic evidence of antibody mediated rejection) on protocol biopsies may be associated with future clinical antibody mediated rejection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subsequent evidence of chronic allograft injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/82\">",
"       82",
"      </a>",
"      ]. Whether or not treatment of subclinical rejection in this setting has a benefit on long-term graft survival is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In ABO incompatible transplantation, it is not unusual for C4d to be positive on protocol biopsies, and this probably has a different connotation than when seen in HLA incompatible transplantation. Thus, in the early post-transplant setting in ABO incompatible transplantation, reinitiation of plasmapheresis and IVIG is used with graft dysfunction or a rising isoagglutinin antibody titer, but not with evidence of positive C4d staining alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Long-term results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term results for graft and patient outcome using either of these protocols of HLA antibody desensitization are unknown. Early results with both protocols have been encouraging and they have allowed patients to successfully undergo a transplantation procedure that would have otherwise been unavailable to them. Accelerated chronic rejection and early graft loss might be the penalty for attempting to cross the HLA barrier, or conversely, these protocols may help induce a state of accommodation or tolerance with excellent long-term graft function as has been reported in ABOI transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the only long-term follow-up study have found that kidney outcomes with these protocols are similar to those observed with non-extended criteria deceased donor kidneys. In this single center retrospective study, allograft survival rates at one and five years for positive cross-match living donor kidneys were 90 and 69 percent, respectively, while survival rates for negative cross-match control living donor kidneys (matched for gender, race, age, and other factors) were 98 and 81 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     FUTURE OF ABOI AND HLA DESENSITIZATION PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excellent long-term results (with an acceptance of a high rate of AMR in HLA incompatible transplantation and an awareness that early graft loss will be likely be greater than is currently experienced in nonsensitized recipients) are needed to justify the financial cost and resource utilization, particularly with the low dose IVIG protocols. If long-term allograft function is routinely maintained using either of these protocols, an overall financial benefit in terms of health care dollars will be realized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional comparative studies between the high and low dose IVIG protocols are needed. Further information regarding what level of antibody titer may be amenable to transplantation with or without desensitization is also needed, as is information on the appropriate adjunctive desensitization treatments. For patients with the option of continuing hemodialysis or peritoneal dialysis, any long-term survival benefit from transplantation using an intensive desensitization protocol with uncertain results as compared to continued dialysis remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DONOR EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to either ABOI or HLA desensitization is the use of a paired exchange program. Although fraught with ethical and potentially legal concerns, willing participants can choose to allow either an ABO or HLA incompatible donor in one case to donate their kidney to an alternate recipient also with an ABO or HLA incompatible donor that is agreeable to donating to their kidney to the remaining recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This process avoids the need for desensitization and provides a living donor allograft to each recipient. Obviously, both parties must be in full agreement and have an understanding of the potential post-transplantation ramifications as well as making a decision on whether or not the parties should remain anonymous to one another.",
"   </p>",
"   <p>",
"    Paired exchange programs can help provide allografts to a select number of individuals. In a single center study, for example, marked success was reported among 22 patients who received ten paired donations including two triple exchanges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/87\">",
"     87",
"    </a>",
"    ]. However, this approach is unlikely to have a significant impact on reducing the wait list time when the exchange program is confined to an individual transplant center.",
"   </p>",
"   <p>",
"    Increasing the exchange programs to a regional or national level would potentially expand the number of suitable donor pairs considerably. This was shown in a modeling study in which the success of such programs was analyzed using increasing population sizes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/88\">",
"     88",
"    </a>",
"    ]. In the United States, a donor kidney exchange program was implemented in Region 1 of the United Network for Organ Sharing system, resulting in limited early success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/33\">",
"     33",
"    </a>",
"    ]. Development of a national kidney paired donation system is underway in the United States through the Organ Procurement and Transplantation Network (OPTN).",
"   </p>",
"   <p>",
"    The use of donor exchange programs to perform wait list exchange (wherein the incompatible donor donates to an individual on the waiting list and the incompatible recipient moves to the front of the wait list) as compared to paired exchange is somewhat controversial. This process may result in even longer delays for those patients already with the longest wait times, in particular blood group O recipients. Such a strategy may not be acceptable to some patients, particularly those with blood group O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Acceptable mismatch program",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, an acceptable mismatch program is in place that assists in providing DDA to highly sensitized individuals through an enhanced distribution and immunologic screening protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/48/34570/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Using this protocol, there is no statistically significant difference in graft survival in the highly sensitized recipients versus that of non-HLA sensitized recipients.",
"   </p>",
"   <p>",
"    Despite success with these programs in increasing the likelihood of an acceptable DDA being offered to a potential recipient highly sensitized to HLA antigens, some authors note that a pool of patients remain essentially non-transplantable secondary to broad immunogenicity. For this reason, further investigation of desensitization protocols continues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20758317\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant number of kidney transplant candidates have living donors that are HLA or ABO blood group incompatible, but otherwise able to donate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Highly sensitized individuals without potential living donors face extremely long wait times on the deceased donor allograft list. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Densensitization protocols using",
"      <span class=\"nowrap\">",
"       plasmpheresis/immunoadsorption",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IVIG, with or without adjunctive therapies",
"      <span class=\"nowrap\">",
"       (splenectomy/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"        rituximab",
"       </a>",
"       )",
"      </span>",
"      can allow for successful transplantation in select recipients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Desensitization protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Higher rates of acute antibody mediated rejection (AMR) are seen in ABO- and HLA-incompatible recipients, particularly when crossing both immunologic barriers. Vigilance with early detection and treatment of rejection is essential for maximizing short-and long-term graft survival. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'ABO incompatibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney paired donation is an alternative or can be used in conjunction with desensitization for the kidney transplant recipient with an incompatible donor. Several KPD programs exist, with the launch of a nationwide KPD system pilot program in 2010. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Donor exchange'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     2008 OPTN/SRTR Annual Report: Transplant Data 1998 - 2007. www.ustransplant.org (Accessed 2/10).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/2\">",
"      Glotz D, Antoine C, Duboust A. Antidonor antibodies and transplantation: how to deal with them before and after transplantation. Transplantation 2005; 79:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/3\">",
"      Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/4\">",
"      Tanabe K, Takahashi K, Agishi T, et al. Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood type incompatible couples. Transfus Sci 1996; 17:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/5\">",
"      Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/6\">",
"      Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/7\">",
"      Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/8\">",
"      Tyd&eacute;n G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/9\">",
"      Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/10\">",
"      Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/11\">",
"      Norman DJ, Prather JC, Alkhunaizi AM, et al. Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade. Transplant Proc 2001; 33:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/12\">",
"      Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/13\">",
"      Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001; 1:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/14\">",
"      Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/15\">",
"      Bryan CF, Winklhofer FT, Murillo D, et al. Improving access to kidney transplantation without decreasing graft survival: long-term outcomes of blood group A2/A2B deceased donor kidneys in B recipients. Transplantation 2005; 80:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/16\">",
"      Toki D, Ishida H, Horita S, et al. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 2009; 88:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/17\">",
"      Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/18\">",
"      Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/19\">",
"      Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation--single center analysis. Am J Transplant 2007; 7:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/20\">",
"      Tyd&eacute;n G, Donauer J, Wadstr&ouml;m J, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/21\">",
"      Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/22\">",
"      Padmanabhan A, Ratner LE, Jhang JS, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation 2009; 87:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/23\">",
"      Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/24\">",
"      Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985; 28:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/25\">",
"      Alexandre GP, Squifflet JP, De Bruy&egrave;re M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19:4538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/26\">",
"      Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 70:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/27\">",
"      Gloor JM, Lager DJ, Fidler ME, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/28\">",
"      Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/29\">",
"      Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/30\">",
"      Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/31\">",
"      Segev DL, Simpkins CE, Warren DS, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/32\">",
"      Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/33\">",
"      Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/34\">",
"      Onitsuka S, Yamaguchi Y, Tanabe K, et al. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999; 13 Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/35\">",
"      Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/36\">",
"      Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/37\">",
"      Tobian AA, Shirey RS, Montgomery RA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/38\">",
"      Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/39\">",
"      Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83:727.",
"     </a>",
"    </li>",
"    <li>",
"     2008 OPTN/SRTR Annual Report: Transplant Data 1997 - 2007. www.ustransplant.org (Accessed 2/10).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/41\">",
"      Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/42\">",
"      Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/43\">",
"      El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005; 66:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/44\">",
"      van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/45\">",
"      Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/46\">",
"      Fuggle SV, Martin S. Toward performing transplantation in highly sensitized patients. Transplantation 2004; 78:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/47\">",
"      Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/48\">",
"      Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003; 3:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/49\">",
"      Jordan SC, Tyan D, Czer L, Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998; 2:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/50\">",
"      Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/51\">",
"      Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/52\">",
"      Toyoda M, Zhang XM, Petrosian A, et al. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994; 2:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/53\">",
"      Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/54\">",
"      Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/55\">",
"      Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/56\">",
"      Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/57\">",
"      Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/58\">",
"      Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/59\">",
"      Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/60\">",
"      Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/61\">",
"      Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/62\">",
"      Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/63\">",
"      Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/64\">",
"      Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/65\">",
"      Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/66\">",
"      Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/67\">",
"      Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/68\">",
"      Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/69\">",
"      Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/70\">",
"      Schiff RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997; 17:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/71\">",
"      Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/72\">",
"      Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/73\">",
"      Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/74\">",
"      Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/75\">",
"      Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/76\">",
"      Haas M, B&ouml;hmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/77\">",
"      Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/78\">",
"      Mulley WR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/79\">",
"      Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/80\">",
"      Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/81\">",
"      Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/82\">",
"      Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/83\">",
"      Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/84\">",
"      Delmonico FL, Morrissey PE, Lipkowitz GS, et al. Donor kidney exchanges. Am J Transplant 2004; 4:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/85\">",
"      de Klerk M, Keizer KM, Claas FH, et al. The Dutch national living donor kidney exchange program. Am J Transplant 2005; 5:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/86\">",
"      Johnson RJ, Allen JE, Fuggle SV, et al. Early experience of paired living kidney donation in the United kingdom. Transplantation 2008; 86:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/87\">",
"      Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/88\">",
"      Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005; 5:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/89\">",
"      Ackerman PD, Thistlethwaite JR Jr, Ross LF. Attitudes of minority patients with end-stage renal disease regarding ABO-incompatible list-paired exchanges. Am J Transplant 2006; 6:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/90\">",
"      Doxiadis II, Smits JM, Persijn GG, et al. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/48/34570/abstract/91\">",
"      Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78:190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7351 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34570=[""].join("\n");
var outline_f33_48_34570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20758317\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ABO DESENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ABO incompatibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - ABO blood groups and antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20757822\">",
"      - ABOI protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Long-term results in ABOI transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Is splenectomy necessary?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20758057\">",
"      - Is rituximab necessary?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      A question of accommodation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Isoagglutinin antibody titers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HLA SENSITIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Types and importance of anti-HLA antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Determination of sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Crossmatch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complement dependent cytotoxicity (CDC or standard NIH-CDC)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ELISA test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      What we test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary and risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DESENSITIZATION PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Use of IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - High dose IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Low dose IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnosis and treatment of AMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Long-term results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      FUTURE OF ABOI AND HLA DESENSITIZATION PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DONOR EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Acceptable mismatch program",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20758317\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7351|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/47/34558\" title=\"algorithm 1\">",
"      Algorithm for the diagnosis of AMR with allo dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/53/12126\" title=\"algorithm 2\">",
"      Algorithm for the diagnosis of AMR without allo dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_48_34571="Prevalence overwt discrepancies";
var content_f33_48_34571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of the prevalence of overweight grade I (BMI &gt;30 kg/m2) using the Behavioral Risk Factor Surveillance System (BRFSS) telephone survey versus the National Center for Health Statistics Surveys",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Survey Year",
"      </td>",
"      <td class=\"subtitle1\">",
"       BRFSS Telephone Survey",
"      </td>",
"      <td class=\"subtitle1\">",
"       National Center for Health Statistics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Indirect Measurement, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Direct measurement, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1960-62",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       14.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1971-75",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       14.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1976-80",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"      <td>",
"       14.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1988-94 (1991)",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       22.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1996",
"      </td>",
"      <td>",
"       15.8",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1998",
"      </td>",
"      <td>",
"       17.9",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1999-2000",
"      </td>",
"      <td>",
"       19.8",
"      </td>",
"      <td>",
"       30.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1999-2002",
"      </td>",
"      <td>",
"       21.3",
"      </td>",
"      <td>",
"       30.6",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from George A Bray, MD. Copyright &copy;2005 George A Bray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34571=[""].join("\n");
var outline_f33_48_34571=null;
var title_f33_48_34572="Classification of juvenile localized scleroderma";
var content_f33_48_34572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of juvenile localized scleroderma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Main group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        (1) Circumscribed morphea",
"       </td>",
"       <td>",
"        (a) Superficial",
"       </td>",
"       <td>",
"        Oval or round circumscribed areas of induration limited to epidermis and dermis, often with altered pigmentation and violaceous, erythematous halo (lilac ring). They can be single or multiple.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (b) Deep",
"       </td>",
"       <td>",
"        Oval or round circumscribed deep induration of the skin involving subcutaneous tissue extending to fascia and may involve underlying muscle. The lesions can be single or multiple. Sometimes the primary site of involvement is in the subcutaneous tissue without involvement of the skin.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        (2) Linear scleroderma",
"       </td>",
"       <td>",
"        (a) Trunk/limbs",
"       </td>",
"       <td>",
"        Linear induration involving dermis, subcutaneous tissue and, sometimes, muscle and underlying bone and affecting the limbs and the trunk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        (b) Head",
"       </td>",
"       <td>",
"        <em>",
"         En coup de sabre",
"        </em>",
"        (ECDS). Linear induration that affects the face and the scalp and sometimes involves muscle and underlying bone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parry Romberg or progressive hemifacial atrophy loss of tissue on one side of the face that may involve dermis, subcutaneous tissue, muscle and bone. The skin is mobile.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        (3) Generalized morphea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Induration of the skin starting as individual plaques (four or more and larger than 3 cm) that become confluent and involve at least two out of seven anatomic sites (head-neck, right upper extremity, left upper extremity, right lower extremity, left lower extremity, anterior trunk, posterior trunk).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        (4) Panclerotic morphea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Circumferential involvement of limb(s) affecting the skin, subcutaneous tissue, muscle and bone. The lesion may also involve other areas of the body without internal organs involvement.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        (5) Mixed morphea",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Combination of two or more of the previous subtypes. The order of the concomitant subtypes, specified in brackets, will follow their predominant representation in the individual patient [ie, mixed morphea (linear-circumscribed)].",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Associated conditions: lichen sclerosus et atrophicus (LSA) and atrophoderma of Pasini and Pierini (APP) can be associated with the previous subtypes but are not included in the above classification. Source: Consensus conference, Padua, Italy, 2004.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34572=[""].join("\n");
var outline_f33_48_34572=null;
var title_f33_48_34573="Effect of methemoglobin";
var content_f33_48_34573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of methemoglobin on measured oxygen saturation by pulse oximetry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nellcor SpO2 reading (blue circles) and true SaO2 (red squares) versus MetHb percent at FiO1 = 1.0.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Barker, SJ, Tremper, KK, Hyatt, J, Anesthesiology 1989; 70:112.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34573=[""].join("\n");
var outline_f33_48_34573=null;
var title_f33_48_34574="Cancer incidence in females in more and less developed countries";
var content_f33_48_34574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Cancer incidence in females in more and less developed countries*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Comparison of the most common cancers in more and less developed countries in 2000.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stewart B, Kleihues P. World Cancer Report,&nbsp;IARC Press, Lyon 2003. Copyright &copy; 2003 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34574=[""].join("\n");
var outline_f33_48_34574=null;
var title_f33_48_34575="Chickenpox rash PI";
var content_f33_48_34575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chickenpox rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chickenpox is an infection that causes itchy, red bumps to form on your skin. It is caused by a virus called varicella.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_48_34575=[""].join("\n");
var outline_f33_48_34575=null;
